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ABSTRACT:
The purpose of this study was to determine whether patients with plantar fasciitis
who are treated with autologous conditioned plasma (ACP®) will lead to reductions in
pain and improved function at one year post-treatment compared to the best available
alternative treatment, corticosteroid injection. This thesis represents an interim analysis of
14 participants three months post randomization. We used the American Orthopaedic
Foot and Ankle Midfoot Society Scale (AOFAS), Plantar Fasciitis Pain/Disability Scale
(PFPD) and SF-12 to measure outcome. The confidence intervals around the betweengroup differences for all outcomes were wide and inconclusive. A larger number of
participants are required to make more definitive conclusions.

Key words: Plantar Fasciitis, Autologous Conditioned Plasma, Corticosteroid, Platelet
Rich Plasma, Quality of Life, Pain, Function
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Chapter 1: Introduction
Plantar fasciitis is the most common cause of inferior foot pain (Roxas 83-93;
Rompe 100-104; Neufeld and Cerrato 338-346; Yucel et al. 105-110). It is estimated that
one in ten persons will experience inferior heel pain in their lifetime. Eighty percent of
these patients are diagnosed with plantar fasciitis. Approximately 30% of patients with
plantar fasciitis will have bilateral pain (Roxas 83-93; Neufeld and Cerrato 338-346).
Although most cases resolve within six months, traditional treatment regiments such as
orthotics, corticosteroid injection and physical therapy are occasionally unsuccessful in
treating this condition, leading to chronic symptoms (Roxas 83-93; Rompe 100-104;
Neufeld and Cerrato 338-346).
As a result of degeneration of the plantar fascia - an arch supporting ligament of
the foot - patients with plantar fasciitis often have pain and tenderness upon palpation of
the medial aspect of the calcaneus. Plantar fasciitis manifests predominantly in those
subjected to sustained weight bearing or repetitive impact activities (Roxas 83-93; Rompe
100-104; Neufeld and Cerrato 338-346). Despite the numerous treatment options utilized
in the management of plantar fasciitis, an option that ensures the relief of symptoms is yet
to be found. For this reason, plantar fasciitis is often a frustrating disorder to treat for both
the patient and the clinician (Roxas 83-93; Neufeld and Cerrato 338-346; Tatli and
Kapasi 3-9).
Research has shown the potential of platelet rich plasma (PRP) to accelerate
wound healing in a variety of conditions including maxillo-fascial surgery, plastic
surgery, chronic wound healing and orthopaedics (Creaney and Hamilton 314-320; Hall
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et al. 602-608). PRP utilizes the patient’s own platelets for their natural healing capacity.
Platelets are central players in clotting, inflammation and the wound healing response
(Creaney and Hamilton 314-320; Hall et al. 602-608; Barrett and Erredge 37).
Autologous conditioned plasma (ACP®) is a subset of PRP. In comparison with
other subsets of PRP, ACP® has a unique platelet concentration, separation process and
activation method. Treatment with ACP® involves taking a blood sample from the
patient, isolating the platelets and injecting them back into that patient at the injury site
(Hall et al. 602-608, Arthrex Research and Development). Previous research indicates
that ACP® may be useful in treating chronic wounds believed to be physiologically
similar to the underlying mechanism of plantar fasciitis (Creaney and Hamilton 314-320;
Hall et al. 602-608; Barrett and Erredge 37).
Corticosteroid injection is the current standard of treatment used for patients that
are resistant to conservative methods of treatment (ie. physical therapy). Current literature
supports its use for short-term relief of pain. However, adverse events - including fat pad
atrophy and rupture of the plantar fascia - have been linked to successive corticosteroid
injections. This study will explore whether ACP® may be a safe and effective alternative
to corticosteroid injection (Crawford et al 974-97; Kenneth and Anderson 427-434;
Neufeld and Cerrato 338-346; Porter and Shadbolt 119-124; Roxas 83-93; Tatli and
Kapasi 3-9; Yucel et al 105-110).
This study will compare a novel treatment - ACP® - to the standard treatment corticosteroid injection - to treat participants with plantar fasciitis. Pain relief, improved
function and quality of life will be used to compare outcomes (Porter and Shadbolt 119124, Yucel et al. 105-110). We believe that there will be no difference in participants

Chapter One: Introduction

with plantar fasciitis treated with ACP® compared to those treated with corticosteroid
injection, leading to an alternative treatment option for this condition.
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Chapter 2: Literature Review
2.1: Plantar Fasciitis
Plantar fasciitis is a degenerative process of the plantar fascia that manifests
clinically as inferior heel pain concentrated at the anteromedial aspect of the calcaneus
(Roxas 83-93; Neufeld and Cerrato 338-346; Thomas et al Sl-19). Plantar fasciitis most
commonly develops due to repetitive microtrauma at the plantar fascia origin, however,
the exact etiology remains unknown (Neufeld and Cerrato 338-346; Roxas 83-93; Tatli
and Kapasi 3-9; Thomas et al Sl-19). Historically, the literature attributed plantar
fasciitis as a result of tuberculosis or entrapment of the first branch of the lateral plantar
nerve or heel spurs; however these propositions have since been discredited (Neufeld and
Cerrato 338-346; Roxas 83-93; Thomas et al Sl-19).
2.2: Epidemiology
It is estimated that one in ten persons will experience inferior heel pain in their
lifetime. Eighty percent of these patients are diagnosed with plantar fasciitis.
Approximately 30% of patients with plantar fasciitis will have bilateral pain (Roxas 8393; Neufeld and Cerrato 338-346). Fifty percent of patients with plantar fasciitis also
present with heel spurs, but the spurs are not always symptomatic (Roxas 83-93; Neufeld
and Cerrato 338-346; Thomas et al Sl-19). Although conservative treatment is successful
in 90% of cases, people afflicted with this disease can expect to have symptoms as long
as six to 12 months (Roxas 83-93; Neufeld and Cerrato 338-346; Thomas et al Sl-19).
Plantar fasciitis is most common in women 40 to 60 years old. The diminished
healing capacity documented in older adults may contribute to the development and
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retention of symptoms. Plantar fasciitis often presents in those with increased tensile load
on the plantar fascia, such as running athletes or people with occupations that require
prolonged standing. Poor biomechanics and anatomical variation, such as pes planus and
less than 10 degrees of dorsiflexion, may predispose individuals to plantar fasciitis. It has
been shown that grade II obesity (greater than 30 kg/m BMI), peripheral neuropathy (ie.
neuropathy secondary to diabetes mellitus), inadequate footwear and seronegative
arthritis - which can cause disease at the site of attachments of ligaments and tendons increases the risk of developing plantar fasciitis (Roxas 83-93; Neufeld and Cerrato 338346; Riddle et al 872-877; Thomas et al S I-19).
2.3: Plantar Fascia
The plantar fascia (Figure 1A) is a fibrous sheet of connective tissue that supports
the foot arch and acts as a shock absorber for the foot and leg (Roxas 83-93; Yucel et al
105-110). The thicker, central portion of the plantar fascia - which is flanked by thinner,
lateral and medial portions - spreads into five digital bands at the metatarsophalangeal
joints. The plantar fascia is essentially inelastic, having only a four percent maximal
change in elongation (Tatli and Kapasi 3-9; Neufeld and Cerrato 338-346).
2.4: Mechanism o f Injury
Dorsiflexion, such as during the toe-off phase of walking gait, creates a high
tensile force concentrated at the origin of the plantar fascia. This process was termed the
“windlass mechanism” by Hicks. The repeated stress at the plantar fascia origin is
believed to predispose to the development of plantar fasciitis (Figure 2) (Tatli and Kapasi
3-9; Neufeld and Cerrato 338-346).
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Figure 1. The point of greatest tenderness of plantar fascia pain during the windlass
mechanism (Goldman).

2.5: Diagnosis
Diagnosis is made following the patient history and clinical examination of the
foot, stance and walking gait. The most simple and straightforward diagnosis involves
identifying the presence of pain and point tenderness upon palpation of the medial
tubercle of the calcaneus. The patient may have tenderness along the entire length of the
plantar fascia. Achilles contracture is frequently present (Kenneth and Anderson 427-434;
Neufeld and Cerrato 338-346, Tatli and Kapasi 3-9; Thomas et al S I-19).
Patients report pain with the first steps of the morning and with continued weight
bearing. The pain may lessen with activity, but will increase by the end of the day. The
stance and gait should be evaluated for planus or pes cavus (Kenneth and Anderson 427434; Neufeld and Cerrato 338-346, Tatli and Kapasi 3-9; Thomas et al S 1-19). Symptoms
may be exacerbated with passive dorsiflexion or exercises that stretch the plantar fascia
(Kenneth and Anderson 427-434; Neufeld and Cerrato 338-346, Tatli and Kapasi 3-9;
Thomas et al S I-19). Patients that present with radiating pain, hyperesthesias and/or
history of inflammation suggest an alternative diagnosis (Thomas et al S I-19).
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Compression of the first branch of the lateral plantar nerve or of the medial calcaneal
nerve, calcaneal stress fracture, tarsal tunnel syndrome, L5-S1 radiculopathy, peripheral
neuropathies, flexor hallucis tendinitis, rupture of the plantar fascia or fat pad atrophy
should be ruled out as competing diagnoses (Kenneth and Anderson 427-434; Neufeld
and Cerrato 338-346).
Although imaging is rarely employed for the diagnosis of plantar fasciitis,
ultrasound is the imaging modality of choice due to feasibility, convenience and safety.
The ultrasound image will show a thickened, hypoechoic fascia. Triple-phase bone scan
and magnetic resonance imaging (MRI) can also be used to properly diagnosis the
disease. A positive plantar fasciitis diagnosis will be exhibited with increased uptake at
the plantar fascia origin on a triple phase bone scan. MRI displays augmented intensity of
signal and thickening of the plantar fascia. If the plantar fasciitis has not resolved within
four to six months, triple phase bone scan or MRI may be used to exclude other
pathological causes.
Histological analysis of the diseased plantar fascia typically shows evidence of
collagen necrosis, microtears of the fascia and myxoid degeneration. Inflammation and
fibroblastic proliferation may or may not be present. Although the name of this disease
suggests inflammation, it is not necessary for diagnosis (Roxas 83-93; Neufeld and
Cerrato 338-346). For this reason, in recent years this condition has been more correctly
referred to as plantar fasciosis (Thomas et al SI -19). Confirmation of heel spurs using
radiography usually indicates the presence of this condition for six to 12 months,
although it may have been asymptomatic (Roxas 83-93; Neufeld and Cerrato 338-346;
Thomas et al S1-19).
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2.6: Treatment
The literature examining the effectiveness of each treatment option is weak and as
a result is inconsistent in its findings and recommendations (Roxas 83-93; Tatli and
Kapasi 3-9; Neufeld and Cerrato 338-346).
Typically, patients diagnosed with plantar fasciitis in the primary care or physical
therapy clinic are instructed to continue activities as tolerated and to avoid flat shoes or
walking bare foot. Since high BMI has been identified as a risk factor for plantar fasciitis,
patients who are overweight are advised to work toward a healthier body composition.
The acute phase of treatment generally ranges from four to six weeks. Initial treatment
consists of anti-inflammatory medication, over-the-counter orthoses and a stretching
program to be completed three times daily and after prolonged sitting (Neufeld and
Cerrato 338-346; Thomas et al S1-19).
Since inflammation is not always present in patients with plantar fasciitis, the
physiological plausibility underlying the effectiveness of non-steroid anti-inflammatory
drugs (NSAIDs) is questionable. Further, there is a lack of clinical evidence for NSAIDs,
although there is some evidence that they provide temporary relief of pain without
resolution of the condition (Neufeld and Cerrato 338-346; Thomas et al Sl-19).
The goal of orthoses is to optimize biomechanical loading of the foot and
minimize excessive pronation. Orthoses have been shown to improve pain levels in
randomized clinical trials (Roxas 83-93; Neufeld and Cerrato 338-346; Pfeffer et al 214221).
All patients with plantar fasciitis are prescribed a physical therapy regimen. To
help alleviate symptoms, stretching of the muscles originating at the volar calcaneus - the
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abductor digiti minimi quinti, digitorum brevis, quadrates plantae, and adductor hallucis will lead to the release of muscle tightness (Figure 2). Stretching therapy is believed to be
beneficial because it releases the plantar foot muscles (Tatli and Kapasi 3-9).
A

Figure 2. A. The muscles of the foot. In diagram B, the outer layer has been removed to
visualize the underlying muscles (Norman).
If symptoms have failed to resolve or to improve after four to six weeks,
alternative modalities such as corticosteroid injection, Botulinum toxin A injection
(Botox), alternative physical therapy, custom orthoses, and prescription NSAIDs may be
explored. Botox paralyses the injected muscle and has direct analgesic and anti
inflammatory properties. Custom orthoses are tailored to correct patient-specific
abnormal loading. Compared to over-the-counter NSAIDs, prescription NSAIDs are
more effective at reducing inflammation (Neufeld and Cerrato 338-346; Thomas et al Sl19).
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Night splints, which secure the foot in neutral position while sleeping, may also
be prescribed. These splints passively stretch the plantar fascia and calf muscles, while
giving the plantar fascia an opportunity to heal (Roxas 83-93). Four to six weeks
immobilization with a cast or short-leg walking boot may also be recommended (Thomas
et al S I-19). At this time, MRI or triple phase bone scan is recommended to confirm
diagnosis and rule out occult pathology (Neufeld and Cerrato 338-346).
For cases lasting six months or longer, extracorporeal shockwave therapy (ESWT)
or surgery may be indicated. ESWT targets acoustic impulses (shock waves) at the
plantar fascia origin. Although the underlying therapeutic mechanism is speculative,
Ogden hypothesized that the impulses may cause microdisruption of the tissue, which
initiates a healing response (Neufeld and Cerrato 338-346). The healing response
promotes revascularization, release of growth factors and recruitment of stem cells,
ultimately leading to healing and resolution of symptoms (Kenneth and Anderson 427434; Neufeld and Cerrato 338-346; Thomas et al S I-19).
2.7: Physical Therapy
The goal of physical therapy treatment is to optimize the tension of the fascia
during walking gait to prevent long-term strain. Stretching the Achilles-tendon,
gastrocnemius, soleus, intrinsic muscles of the foot and plantar fascia will target all
regions that may benefit the patient. Activities to target the intrinsic muscles of the foot
include ‘towel curls’, ‘toe taps’ and picking up marbles with the toes.
For towel curls, the patient is instructed to put his or her heel on the towel at one
end and pull the remainder of the towel toward the heel using the toes (Roxas 83-93). To
specifically target the plantar fascia with a controlled dynamic stretch, the patient can
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resist the toes in dorsiflexion. With the opposing hand, the patient should simultaneously
confirm tension in the plantar fascia via palpation. The patient may also roll their foot
over a tennis ball or 12-oz can to stretch the plantar fascia (Roxas 83-93; Neufeld and
Cerrato 338-346).
The goal of an Achilles stretching programs is to lengthen the gastrocnemius and
soleus muscles. To stretch the gastrocnemius and soleus muscle groups, the patient places
one foot in front of the other in a lunge position so the back foot is in dorsiflexion. The
patient may chose to perform this stretch while facing and pushing their hands into a
wall. Both feet should be pointed straight forward or toward the wall. The back leg is
straightened, while the front leg knee is flexed. A stretch should be felt in the calf. Next,
both knees are flexed to isolate the soleus muscle. Maximizing the length of the Achilles
tendon can be achieved by resisting the metatarsal region in dorsiflexion on a stool or
step (Roxas 83-93; Neufeld and Cerrato 338-346).
DiGiovanni et al. (2003) conducted a prospectively, unblinded, randomized clinic
trial to assess the difference in pain between 101 participants allocated to a non-weight
bearing plantar fascia stretching or weight bearing Achilles tendon-stretching program.
The non-weight bearing plantar fascia stretching program instructed the participants to
use resisted, controlled stretching as previously described. The weight bearing Achilles
tendon regimen focused on stretching the gastrocnemius and soleus muscles while
standing and leaning with both hand pushing against the wall as previously described.
At eight weeks, the Foot Function Index (FFI) showed significantly better results
in the plantar fascia stretching program with respect to overall pain {p = 0.02) and pain
with the first steps of the morning (p = 0.006). Activity limitations and overall participant
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satisfaction were found to be significantly better in the plantar fasciitis stretching group.
This study demonstrated the benefit of more specific plantar fascia stretching programs as
opposed to Achilles stretching programs commonly prescribed (DiGiovanni et al 12701277).
Within the general healthcare community, it is accepted that stretching and
strengthening are beneficial for the musculoskeletal system. Research has shown that
physical therapy helps to relieve symptoms and to decrease the recurrence of symptoms
by improving proper biomechanical loading during stance and walking gait. Previous
studies have also investigated therapeutic ultrasound, iontophoresis, low-intensity laser
therapy and exposure to an electron-generating device. However, current research has not
shown these treatments to be effective in treating plantar fasciitis (Neufeld and Cerrato
338-346).
2.8: Corticosteroid Injection
Although the empirical evidence to support the effectiveness of corticosteroid
injection is not strong, corticosteroids are typically used for patients resistant to
conservative therapy. In theory, the effectiveness of corticosteroid is rooted in its activity
as an anti-inflammatory agent, however, little is known of its action at the cellular level.
Current literature supports its use for the short-term relief of pain (Roxas 83-93; Tatli and
Kapasi 3-9; Neufeld and Cerrato 338-346).
The injection - typically using a 25-gauge, 1.5-inch needle - is inserted perpendicular
to the skin at the maximum area of tenderness. The injection should be administered past
the midline of the foot slowly and evenly, with care taken to avoid the fat pad. The
patient should remain in the supine position for several minutes post-injection and
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monitored for adverse events for 30 minutes before leaving the clinician’s office. It is not
uncommon for symptoms to worsen for the first 24 to 48 hours, which can be treated with
rest, ice, elevation and compression. Typically, a follow-up visit is arranged three weeks
after injection (Tallia and Cardone 1356-1362).
Yucel et al. (2010) prospectively compared one session of high-energy ESWT to one
combined betamethasone diproprionate, betamethasone sodium phosphate and prilocaine
hydrochloride 2% injection (corticosteroid injection) in 60 randomized, unblinded
participants assessed three months post-treatment. Participants with unsuccessful therapy
for at least six months were included in the study. Only heel cups were permitted as
additional treatment during the trial.
Both treatments resulted in improvements in participant-assessed pain and physicianassessed tenderness (p< 0.05), but no significant difference was found between
treatments. A decrease in the VAS or heel tenderness index score of at least 50% from
baseline and a loss of tenderness was considered an acceptable therapeutic response. This
criterion was met in 27 of 33 participants who received the corticosteroid injection and 23
of 27 participants that received the ESWT (OR = 1.28 (95% Cl 0.32, 5.1), p = 0.73). This
study showed that a single corticosteroid injection was successful in producing a
therapeutic response in the majority of participants (Yucel et al 105-110).
Porter and Shadbolt (2005) conducted a prospective, randomized, observer-blinded
study to compare one intralesional betamethasone plus lignocaine 1% injection
(corticosteroid injection) to low-energy ESWT. The low energy ESWT treatment was
administered three times over a three week period. Non-randomized participants that
underwent a plantar fascia and Achilles tendon stretching program for 12 months were
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included as controls. All 132 participants included in the study presented with symptoms
of at least six weeks duration and refrained from other treatments with the exception of
heel cups for the duration of the study. All randomized participants also participated in
the stretching program. Daily pain was assessed using a pain 10 mm VAS and threshold
tenderness at the plantar fascia origin.
At three months, the corticosteroid group had significantly lower VAS pain scores
compared to controls (MD = 2.1 (95% Cl -10.1 to 14.3) and the ESWT group (MD = 2.2
(95% Cl -6.1 to 10.6)). The average tenderness threshold levels was significantly higher
in the corticosteroid group compared to the ESWT group (MD -2.7 (95% Cl -8.1 to 2.7)
and controls (MD = -1.8 (95% Cl -5.4 to 1.8)). At 12 months, the low energy ESWT and
corticosteroid group had significantly lower pain scores compared to controls (ESWT
vs.control MD =1.6 (95% Cl -5.3 to 8.4); corticosteroid vs. control MD =1.6 (95% Cl 12.0 to 15.1)). The ESWT and corticosteroid groups’ VAS pain scores were not
significantly different. By 12 months, all three groups had similar levels of average
threshold tenderness at the higher end of the range, with the average in the corticosteroid
group remaining approximately similar to the values recorded at three months
(corticosteroid vs. control MD = 0.2 (95% Cl -2.9 to 3.4); corticosteroid vs. ESWT MD =
0 (95% Cl -2.4 to 2.4); ESWT vs. control MD = 0.2 (95% Cl -3.0 to 3.5)). The
investigators concluded a corticosteroid injection was as effective, and more affordable
than ESWT. This study supported the use of corticosteroid treatment as one of the current
standards for the treatment of plantar fasciitis (Porter and Shadbolt 119-124).
Crawford et al (1999) conducted a randomized, prospective clinical trial evaluating
the efficacy of corticosteroid for 106 participants with “pain and tenderness centred on
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the medial tubercle of the calcanéum on weight bearing after rest, which resolved, either
partially or fully, after activity”. The four treatment arms were prednisolone with 2%
lignocaine acetate (corticosteroid injection); corticosteroid injection given after a tibial
nerve block, 1% lignocaine hydrochloride (local anaesthetic) and local anaesthetics given
after tibial nerve block. Outcome assessor, treating physician and participants were all
blinded to their treatment allocation throughout the duration of the study.
Analysis of the data showed a significant statistical reduction in pain one month
following corticosteroid injection (plus local anesthesia) in comparison to local anesthetic
with or without tibial nerve block (corticosteroid plus local anesthesia vs. local anesthesia
MD =1.1 (-0.4 to 2.6); corticosteroid plus local anesthesia vs. local anesthesia with tibial
block MD = 1.6 (95% Cl 0.2 to 3.0))). Further statistical difference was not evident after
one month. The authors concluded that corticosteroid had short-term effectiveness and
that locally anaesthetizing participants did not appear to improve participant comfort.
This study further supported the use of corticosteroid injection treatment in treating
participants with plantar fasciitis (Crawford et al 974-977).
Patients treated with betamethasone may be administered a local anaesthetic prior to
the corticosteroid injection. According to the literature, local anaesthetics such as
Xylocaine® may have therapeutic effects equal to that of corticosteroid. When
considering a new treatment or examining therapeutic effects, local anaesthetic in
addition to the treatment may influence the perception of effect the participant
experiences.
Alvarez et al conducted a randomized clinical trial to compare Xylocaine® to
betamethasone for 58 participants with symptoms of rotator cuff tendinosis or partial cuff
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tear longer than six months. Since eligible participants had more chronic symptoms
(average duration of symptoms was three years), the degenerative changes may be similar
to those with chronic plantar fasciitis. The Western Ontario Rotator Cuff Index (WORC);
American Shoulder and Elbow Surgeons standardized form; Disabilities of the Arm,
Shoulder and Hand; active internal rotation; and the Neer impringement sign were
assessed at two, six, 12 and 24 weeks post-injection.
The authors found no statistically significant difference for all outcomes and time
intervals (3 month WORC MD = -10.9 (95% Cl -2.9 to -18.9), reportedp =0.01; 6 month
WORC MD = -8.0 (95% Cl -23.3 to 7.3),/? = 0.3). Both groups had small improvements
in symptoms that lasted longer than six months. Four theories regarding the two
outcomes were proposed. Either that the injection had a placebo effect that was
demonstrated equally in both groups; that participants followed the natural history of the
disease and each treatment was not effective; that the numbing effects of Xylocaine® had
some carryover effect; or that filling the subacromial space with a five milliliter volume
had therapeutic effects on its own. It was concluded that betamethasone is no more
effective than Xylocaine® in treating patients with chronic rotator cuff tendinosis.
However, it was noted that the scores of the betamethasone group were higher than the
Xylocaine®. It could be that the study was underpowered to find clinically relevant
changes.
2.9: Adverse Effects Linked to Corticosteroid Injection
Documented complications linked to corticosteroid injection include rupture of
the plantar fascia and/or fat pad atrophy. Both adverse events lead to increased pain
(Kenneth and Anderson 427-434; Roxas 83-93; Yucel et al 105-110; Tatli and Kapasi 3-
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9; Neufeld and Cerrato 338-346). Plantar fascia rupture interrupts the windlass
mechanism of the foot and promotes surrounding inflammation. It has also been shown
that corticosteroids suppress proteoglycan synthesis, which might predispose the fascia to
rupturing. Fat pad atrophy exposes the plantar fascia to further assault.
An agent of betamethasone (corticosteroid) was injected into the right Achilles tendon
of thirty New Zealand White Rabbits by investigators Kenny and Willis (1976). One half
of the rabbits were given 0.25 cc and the remaining half were given 0.5 cc, which
corresponds to approximately one quarter and one half of the usual adult dosage,
respectively. To use as controls, 0.25 cc and 0.5 cc of 1% Xylocaine® were administered
to the left Achilles tendon of the rabbits. For ten rabbits, An Instron Tension Analyzer
with a constant loading rate of 12.5cm/min was used for tensile study of the Achilles
tendon complex. To examine Achilles tendon sections, the twenty remaining rabbits were
sacrificed, stained with Hematoxylin and Eosin and viewed with a light microscope.
Rabbits were sacrificed at times ranging from 48 hours to six weeks (Kennedy and Willis
11- 21).
The failing strengths of the Tendo-Achilles at 48 hours were -37.2 Kg and -36.8 Kg in
corticosteroid treated rabbits compared to -56.8 Kg and -54.3 Kg in controls. The failing
strengths returned to that of controls by two weeks. Investigation at the cellular level
revealed necrotic tissue and cystic spaces within the first seven days. As was evident with
disordered collagen deposition, the pathogenic tissue began to resolve in the following
week. By the sixth week, the collagen had reorganized into parallel fibres, signifying
healing. These observations led to the conclusion that corticosteroid weakens tissue at the
injection site, but healing is initiated after the first week. Corticosteroid injection may act
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in the same manner when used to treat patients with plantar fasciitis (Kennedy and Willis
11- 21).

To reduce the incidence of negative side effects, clinicians recommend
pinpointing the location of pain, limiting the number and frequency of injections and
restricting aggressive physical therapy for two weeks post-injection to allow healing. This
is especially important because 50% patients with ruptures have long term complications
(Tatli and Kapasi 3-9). Although it remains controversial, current research has shifted
toward using guiding techniques to localize the corticosteroid injection at the target site
and to attempt to reduce the risk for adverse side effects. Guiding techniques under
investigation include ultrasonography, palpation and scintigraphy (Yucel et al 105-110;
Tatli and Kapasi 3-9; Yucel et al 695-701). At this time, it is recommended that
scintigraphy localization be used in conjunction with the corticosteroid injection in cases
that have failed with more than one corticosteroid injection (Yucel et al 105-110).

2.10: ACP® Treatment
Platelets supplement the natural immune response by increasing mitogenesis synthesis of new cells - and angiogenesis - growth of new blood vessels from pre-existing
vasculature (Marx 225-228). Upon activation, platelets release insulin-like growth factor
(IGF-1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF),
platelet-derived growth factor AA, BB, and AB (PDGF-AA, PDGF-BB, PDGF-AB) and
transforming growth factor-beta (TGF-P). As a result, these growth factors are elevated in
a PRP preparation (Marx 225-228; Arthrex Research and Development; Weibrich et al
693-699; Lynch et al 7696-7700; Hall et al 602-608).
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PRP is defined by having platelet concentration levels that are above the healthy
physiological blood levels. The human physiological range is from 150 000/pL to 350
000/pL with an average of about 200 000/pL (Marx 225-228; Hall et al 602-608).
Currently, four times the original platelet concentration is considered clinically effective,
although there is little evidence in the literature to support this value. There is some
evidence that smaller concentrations may be more effective in increasing cell
proliferation and viability (Hall et al 602-608; Choi et al 420-424).
PRP is autologous, which means it is made from the same person in which it is re
administered. This eliminates immune system induced rejection and the risk of
transferable infections such as human immunodeficiency virus (HIV). Growth factors
secreted by platelets act on the cell membrane instead of the cell nucleus. Activation at
the cell membrane initiates a cascade that result in normal gene expression in the nucleus
(Marx 225-228). For this reason, there is no risk of PRP causing cancer (Marx 225-228;
Hall eta l 602-608).
In order for PRP to be effective in accelerating wound healing, the cells within the
sample must be viable. PRP remains in an anticoagulated and stable state for eight hours
after preparation. The preparation must be administered within this time frame to be
effective (Marx 225-228). ACP® is a PRP subset that has a unique concentration of
platelets and growth factors resulting from unique manipulations of the patient blood
sample (Hall et al 602-608).
2.10.1: The Healing Response
During the normal healing response, damaged tissue releases factors that cause
local vasodilatation. Vasodilatation causes blood to rush to the site of injury. Damaged
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collagen initiates activation of platelets contained within the blood to degranulate and
release growth factors. These growth factors result in hematoma and clot formation.
During this time, neutrophils, macrophages and fibroblasts are activated. Neutrophils and
macrophages phagocytose foreign materials, bacteria and damaged material.
Macrophages also release more growth factors. Next, the fibroblasts produce new
extracellular matrix, which becomes cross-linked and organized during remodeling.
Healing is normally completed within 21 to 28 days after the initial injury (Arthrex
Research and Development; Diegelmann and Evans 283-289).
Central growth factors known to be involved in the healing process include IGF-1,
EGF, VEGF, PDGF and TGF-p. These growth factors are secreted by activated platelets
and therefore, by the platelets in the PRP sample. They have a wide range of influences,
including stimulating myoblasts and fibroblasts, mediating growth and repair of skeletal
muscle (IGF-1); proliferation of epidermal and mesenchymal cells and potentiation of
other growth factors (EGF); stimulation of cell replication, angiogenesis, macrophages,
neurophils, smooth muscle cells and fibroblasts (PDGF); balancing fibrosis, myocyte
regeneration, mitogenesis and collagen synthesis (TGF-p); and promoting angiogenesis
(VEGF) (Arthrex Research and Development; Diegelmann and Evans 283-289; Lynch et
al. 7696-7700).
2.10.2: The A CP® Preparation
For the purpose of this study, the Arthrex ABS-10010S Double Syringe with
Syringe Cap (ACP®-DS) was used to concentrate the platelets and growth factors at the
injury site. The protocol outlined by Arthrex Inc. suggests one milliliter of anticoagulant
should be added to the syringe before taking the blood sample. For the purpose of this
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study, the anticoagulant was not needed because the blood sample was taken and the
ACP® was administered within a very short time frame. The clotting process was not
activated within this time frame.
As Figure 3 illustrates, to prepare an ACP® sample, 10 mL of blood sample is
taken into the larger syringe. The entire syringe is centrifuged for five minutes at 1500
rpm/rcf. This results in separation of the blood components by density. A yellowy plasma
layer containing platelets remains at the surface of the sample. This upper layer is pulled
into the smaller syringe. A small gap between the red blood cell and plasma layer should
remain in the large syringe to avoid contaminating the sample with red blood cells. Once
the smaller syringe is unscrewed from the larger, the syringe is ready to administer to the
patient (Arthrex Research and Development).
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Figure 3. The steps to prepare the ACP® using the double syringe system.
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The same procedure to administer the corticosteroid injection can be used for the
ACP® injection. Care should be taken to avoid injecting the ACP® at the same site as the
Xylocaine® or the fat pad.

2.10.3 The Make-up
Each PRP system produces a sample rich in platelets and growth factors. Arthrex
Incorporated found that the ACP® sample contained two times the platelet concentration,
25 times the PDGF-AB, six times the PDGF-BB, five times the EGF, 11 times the VEGF
and four times the TGF-|3 concentration above baseline levels (Arthrex Research and
Development). The ACP®-DS system eliminates leukocytes, which can release
hydrolyases and proteases that can degrade the ACP® sample (Arthrex Research and
Development; Hall et al 602-608).
Table 1 illustrates the differences between ACP® and other PRP systems on the
market. This table compliments the studies outlining the efficacy of PRP technology
discussed below. The information provided in this table was obtained from product
manufacturers. With the exception of the Biomet GPS III, the company-supplied data are
unpublished (Eppley, Woodell and Higgins 1502-1508; Hall et al 602-608). Although the
other systems may not have the same make-up as ACP®, the findings in the study may be
extrapolated and applied to the ACP® system while keeping in mind the differences
(Arthrex Research and Development).
It is important to note that there are a multitude of factors that will determine the
composition of blood obtained in a sample at any given time and on a patient-to-patient
basis. Therefore, the range over baseline is an average. However, it has been shown that
as little as two to three times the platelet concentration (or 3xl05 platelets/pL) may aid
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the normal healing process and result in accelerated healing (Arthrex Research and
Development; Choi et al 420-424).

2.10.4: In vitro Studies
Sanchez et al (2007) conducted a case-control and descriptive laboratory study
investigating PRP effects using Achilles tendon ruptures. Six athletes underwent open
suture repair with PRP injection. They were retrospectively matched to six athletes that
followed a conventional open suture repair. During a 32 ± 10 month duration in PRP
treated athletes and 50 ± 11 month duration in controls, range of motion, functional
recovery and complications were evaluated in the athletes. Time to recovery was
measured by the duration until participants were able to successfully accomplish a gentle
ran. In the laboratory portion of the study, the investigators measured the platelet
composition and growth factors obtained using the PRGF System II (BTI) in 21
volunteers with ligament, tendon and muscle injuries- -including the six athletes that
underwent Achilles tendon repair.
The athletes that received the PRP injection experienced no wound complications,
earlier recovery of motion (MD = 4.5 weeks (95% Cl 0.8 to 8.2)), less time to recovery
(MD = -7 weeks (95% Cl -10.1 to -4.0)) and earlier return to play (MD = -6.5 weeks
(95% Cl -9.7 to -3.3)). Measured by the Cincinnati Sports Activity Scale, the PRP group
was able to return to scores prior to injury at 14 weeks (range two weeks) (average
baseline score 88 ± 11 points). The average score of control athletes was 82 ± 11 points at
22 weeks (range eight weeks), compared to 90 ± 12 points at baseline. In the laboratory
section of this study, all growth factors - TGF-B1, PDGF-AB, VEGF, EGF, HGF experienced increases similar to those observed for the ACP® system. An average
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Table 1. A comparison of common PRP systems (Hall et al 602-608; Lopez-Vidriero et al 269-278).
Volume of
Blood
(mL)

Autologous
Conditioned
Plasma

9

Final
Centrifuge
PRP
Settings
Time Speed3 Volume
(mL)
(min.)

5

1500
rpm

3-5

Activation agent

None

Leukocytes
in PRP
sample

No

Platelet
Concentration
(above average
blood values)

x 2-3

(Arthrex)

Cascade
(Musculoskele
tal Transplant
Foundation)

GPS III
(Biomet)

#1:6
9 or 18

27 or 54

#2:
15

1450x
g

15

1900x
g

SmartPReP
(Harvest
Technologies)

1900x
g

20 or 60

14

lOOOx
g

2 or 4

Calcium

No

3 or 6

Calcium
chloride/thrombin

Yes

3 or 7

Thrombin

Yes

a Centrifuge settings calculated in the units x gravity (RCF). RCF = 1.12(radius)(RPM/1000)2

N/A

x 4-8

x 4, 4-7, 6

Growth Factor
Concentration
(above average
blood values)
x25 PDGF
x 5 EGF
x 11 VEGF
x 4 TGF-pl
x 1 IGF-1
N/A PDGF
x 5-10 EGF
x 5-10 VEGF
x 5-10 TGF-pl
x 5-10 IGF-1
N/A PDGF
x 3,9 EGF
x 6,2 VEGF
x 3,6 TGF-pl
x 1 IGF-1
x 4.4 PDGF
x 4.4 EGF
x 4.4 VEGF
x 4.4 TGF-pi
N/A IGF-1
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3.10-fold increase (SD, 0.58) in platelet levels (MD = -411 000 (95% Cl -511 697 to 310
303)) with a significant positive correlation with growth factors TGF-lp (r = 0.62,/?
<0.05), PDGF-AB (r = 0.68,/? < 0.05), VEGF (r = 0.60,/? < 0.05), EGF (r = 0.59,/? <
0.05) and HGF (r = 0.6544,/? < 0.05) was observed. Leukocytes were not detected in the
sample (Sanchez et al 245-251). The authors concluded that the preliminary results
obtained in this study suggested that PRP may be beneficial, but randomized clinical
trials are needed. This study provided support for the physiological theory behind ACP®
and its use to accelerate the healing response by increasing platelet and growth factors
concentration at the injury site (Arthrex Research and Development; Hall et al 602-608;
Schneider and Tiidus 837-856).
Anitua et al (2009) obtained 16 donor fibroblast cultures from the skin, synovium
and tendon exposed to PRP or platelet poor plasma (PPP) to investigate if effects are
phenotype-specific. The blood samples to prepare the supernatants were obtained from
two healthy males. The culture medium was supplemented with either supernatant from
platelet-poor fibrin matrix, fibrin matrix supernatant containing 200% of the platelets in
venous blood count or supernatant containing 400% of the platelets in venous blood
count. Considering the cell anatomical origin and platelet dose, cell proliferation,
secretion of angiogenic growth factors (VEGF and HGF), synthesis of type I collagen
factors and hyaluronic acid (HA) was measured. TGF-(3 neutralizing antibody was used
on each sample. Exogenous TGF-p, equal to the amounts of endogenous TGF-P found in
each PRP supernatant preparation, was administered to examine type I procollagen and
HA synthesis (Anitua et al 162-170).
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Compared to non-stimulated cells, significantly greater proliferation was observed
in the cells exposed to the PRP supernatants (p < 0.05). The type I collagen production
was not altered, but enhanced HA, which may be related to augmented TGF-B levels,
was observed (p < 0.05). Greater synthesis of the angiogenic growth factor VEGF was
observed only in the tendon cells, which suggests a relationship between PRP effects and
anatomical origin (p < 0.05). The investigators concluded that PRP effects are related to
concentration, integrity of the cell and cell phenotype. PRP has been shown to be
effective in numerous orthopaedic injuries, but if the effect is phenotype-specific, this
may influence its effect on patients with plantar fasciitis (Anitua et al 162-170).
It has been reported that a double centrifugation is needed to separate the blood
sample to the extent needed to obtain the appropriate platelet and growth factor
concentration. Robert E. Marx argues that with only one spin, the sample consists of PRP
and PPP. PPP decreases the overall amount of platelets within the plasma fraction (Marx
225-228; Hall et al 602-608). The ACP® system uses a single spin to prepare the sample.
A study by Tamimi et al (2007) compared the ACE (double centrifuge) to the
Nahita system (single centrifuge) technique to obtain the PRP sample. Thirty randomly
obtained blood samples underwent both centrifuge systems. Platelet concentration was
analyzed using flow cytometry. Ultrastructural analysis of the PRP sample was analyzed
with transmission electron microscopy (TEM).
Tamimi et al concluded that although a double spin resulted in a slightly higher
average platelet concentration compared to the single spin system (MD = -204 600
plaetelets/mm3 (95% Cl -317 846 to -91 353)), the platelets were effectively concentrated
with only one spin. The variability and range of platelet concentration was greater for two
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spins compared to one. This study supports the ACP® protocol for effectively increasing
platelet concentration using one centrifuge spin. (Arthrex Research and Development;
Tamimi et al 1084-1093).
Although four times the average platelet concentration is the reported acceptable
therapeutic value, there is little support in the literature for this value. The ACP® system
harvests platelet to a concentration of two to three times. More research is needed to
determine the proper harvesting method, ideal platelet concentration and application of
PRP.
Choi et al (2005) conducted an in vitro study using bone alveolar cells from
mongrel dogs to examine the effects of PRP concentration on proliferation and viability.
Cells were cultured for seven days. Cellular outgrowth was observed after two weeks of
incubation. MTT assay and hemocytometer count were used to determine the
proliferation of cells. Using the blood of the mongrel dogs, PRP, PPP and platelet
concentrates were prepared. To prepare the platelet concentrates, one milliliter of PRP
was centrifuged and the supernatant was drawn off. The platelets were re-suspended in
Dulbecco’s Modified Eagle Medium (DMEM) to obtain a suspension devoid of plasma.
Then the suspension was diluted with DMEM to create 1% (11 000 platelets/pL), 5% (55
000 platelets/pL), 10% (110 000 platelets/pL), 20% (220 000 platelets/pL), 30% (330
000 platelets/pL), 50% (550 000 platelets/pL) and 100% (1 100 000 platelets/pL) platelet
concentrate solutions. The PRP and PPP were diluted to create the same concentration
range.
The number of cells decreased in a concentration-dependent manner. In the PRP
concentration, a significant increase in cell viability and proliferation were observed at

Chapter Two: Literature Review 32

1% and 5% (PRP equivalent to two to three times the platelet concentration), however
higher concentrations led to a decrease in viability and proliferation (p < 0.05). The
100% PRP concentration displayed marked toxicity to the cells. Results for PPP were
similar, but higher concentrations were even more cytotoxic to the cells compared to
PRP. Using the PC concentrations, the highest proliferation was found at 30%, with slight
decreases in proliferation and viability at higher concentrations. This study shows that
higher concentrations of PRP may not lead to greater proliferation and viability. It
supports the use of ACP® and the use of lower PRP harvesting systems (Choi et al 420424).
Some PRP preparations combine the sample with an activation agent such as
thrombin and/or calcium chloride prior to injection. The purpose of the activator is to
initiate the clot formation and growth factor release. Although bovine thrombin is
frequently used as an activator, it has shown serious side effects. It can activate
antibodies against prothrombin, thrombin, factor V and cardiolipin. This can result in an
autoimmune syndrome and postoperative bleeding. Thrombin use has also been shown to
decrease the strength of the clot and prevent migration of fibroblasts through the clot. The
ACP® system does not use an activator. It has been shown that the platelets can be
slowly activated by damaged collagen alone, as it is in the normal healing response.
In 2008, Fufa et al examined growth factor release (VEGF, PDGF-AB and TGFpi) for 10 days comparing two methods of activation: rodent type 1 collagen and bovine
thrombin. The PRP samples were prepared using the Harvest Smart PreP2 system
utilizing four blood donors. The PRP preparations were administered into centrifuge
tubes to form clots, incubated and transferred to well plates. Dulbecco’s modified Eagle’s
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medium with 2% antibiotic antimyocotic solution was added to the well plates, followed
by humidified incubation. The width and length of eight clots - four clots with type 1
collagen and four with bovine thrombin activator - were measured everyday for the
duration of the study (Hall et al 602-608; Fufa et al 684-690).
The thrombin-activated clots had greater decrease in area (133 ± 1.7 mm )
compared to the type I collagen clots (74 ± 23 mm2) in the first 24 hours, which persisted
until day five (MD = -59 (95% Cl -64.3 to -53.7). By day 10, the thrombin clot had
disintegrated; while the collagen-activated clot did not significantly diminish any further.
However, the thrombin clot had significantly greater release of growth factors PDGF-AB
and TGF-pi at the initial activation and overall (PDGF-AB MD at 12 hours = -468 ng/g
(95% Cl -618.7 to -317.3); overall MD = -521 ng/g (95% Cl -693.1 to -348.9); TGF- pi
MD at 12 hours = -163 ng/g (95% Cl -340.3, 14.3); MD overall = -616 ng/g (95% Cl 1069.8 to -162.2))). After the first 24 hours, PDGF-AB release was not different between
the two activators. No significant difference in release of VEGF was found. The
experiment showed that type I collagen can be used to activate the PRP clot and release
growth factor with less retraction of the clot compared to bovine activator (Hall et al 602608; Fufa et al 684-690).
Prior to injection, a local anesthetic is often administered to provide temporary
relief of pain. However, local anesthetics such as Xylocaine® and bupivacaine may be
cytotoxic to viable cells. If this is true, the ACP® platelet viability may be affected by
administration of local anesthetic. It is suggested that care should be taken to avoid
injecting the ACP® and local anaesthetic in the same place upon administration.
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Chu et al examined the effects of bupivacaine on human and bovine articular
chondrocytes in vitro. During the study, viability at 30 minutes after exposure to 0.5%,
0.25% and 0.125% bupivacaine solution was measured with fluorescent staining and
confocal microscopy. Saline (0.9%) was used as a control.
After exposure to 0.5% bupivacaine for 30 minutes, human articular chondrocytes
showed greater than 95% cellular death. A positive relationship between duration of
exposure to 0.25% bupivacaine and cytotoxity was observed for human and bovine
chondrocytes. After seven days, chondrocyte viability was 41% of saline controls. The
viability of bovine and human chondrocytes exposed to 0.125% bupivacaine was similar
to that of controls. This study showed that exposure to local anesthetic may be cytotoxic
in a time-dependent manner. This is an important consideration when using local
anaesthetic prior to injecting a viable sample (Chu et al 814-820).
2.10.5: Animal Studies
A study by Lyras et al (2010) investigating full-thickness rabbit patellar tendon
defects treated with PRP compared to non-PRP treated controls showed acceleration of
healing. Eighty-four mature New Zealand rabbits were randomized to four treatment
groups. Six of the twelve rabbits in each treatment arm received a PRP injection in each
limb at each of the sacrificial time points. Twelve rabbits in each group were sacrificed at
either week one, two, three or four to examine longitudinal sections of patellar tendon
stained with haematoxylin and observed with light microscope. Immunexpression of
CD31 - a signature of vascular endothelial cells - was also examined (Lyras et al 143148).
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In the PRP-treated rabbits, accelerated healing was demonstrated by more dense
and mature tissue emphasized in those sacrificed at three weeks compared to the controls
sacrificed at the same time point. Rabbits that received PRP treatment had significantly
higher neovascularisation - measured by cell marker CD31 - in the first two weeks after
injury, but less than controls in weeks three and four (MD at one week = -473 (95% Cl 490 to 456);MD at two weeks = -3300 (95% Cl -3318 to -3282; MD at three weeks =
1649 (95% Cl 1614 to 1684); MD at four weeks = 174 (95% Cl 166 to 182)). With
earlier neovascularisation and mature tissue evident at an earlier time point, the evidence
is compelling that PRP is effective at the tissue level (Lyras et al 143-148).
Another study by Virchenko and Aspenberg (2006) randomized 120 Sprague
Dawley rats to four treatment groups: control group in a normal cage, PRP-injected group
in a normal cage, control group in an activity cage and PRP-injected group in an activity
cage. One post-operative PRP injection was administered to the injured Achilles tendon
in PRP-treated rats. Ten rats were used to prepare the PRP. For 14 days, rats participated
in a loaded or unloaded condition. During the initial phase of healing, rats in the loaded
condition were subjected to mechanical stimulation of the Achilles tendon. In the
unloaded condition, Botulism toxin A (Botox) was administered to the calf of the
participant rats (Virchenko and Aspenberg 806-812).
The investigators found both activity and platelets to independently accelerate
healing compared to inactivity and non-PRP treated rats. PRP-treated rats showed
evidence of significantly earlier healing at days three and five (p < 0.01). On day three,
platelet gel treated rats had 53% (28 to 76) increase in tendon transverse area (mm2)
(mean (95% Cl)). On day five, earlier healing in PRP treated rates was measured by 37%
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(11 to 63) increase in force at failure (N) 52% (15 to 87) increase in stiffness and 64% (25 to 154) increase in tendon transverse area (mm ). These observations were interesting
considering the short half-life of platelet-derived factors. Rats in the unloaded PRP group
were found to have healing effects similar to controls rather than PRP-treated rats in the
loaded condition.
From the experiment, the researchers concluded that PRP had an early affect in
healing that allowed new tendon to be synthesized earlier with mechanical stimulation.
Therefore, rats in the loaded condition were at an earlier point of healing compared to the
unloaded group. It was determined that the mechanical stimulation was needed to
experience the PRP accelerated healing since it was abolished in the unloaded condition.
This may emphasize the need for physiotherapy and loading post-injection (Virchenko
and Aspenberg 806-812).
2.10.6: Clinical studies
One of the earliest case series published in the use of PRP to treat plantar fasciitis
was conducted by Barrett and Erredge (2004). They used the SmartPrep® System
(Harvest Technologies) to prepare three cubic centimeters (cc) of PRP. After
anaesthetization with a posterior tibial peripheral nerve and sural nerve block, nine
participants with chronic plantar fasciitis were administered with PRP at the plantar
fascia origin and then immobilized in a cast. Participants refrained from weight bearing
for 48 hours. They were permitted to return to comfortable shoes in two days. Plantar
fascia thickness and signal intensity were measured by high-frequency ultrasonography at
baseline, one, four, eight, and 12 weeks post-treatment (Barrett and Erredge 37).
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Participants experienced a significant decrease in plantar fascia thickness within
one week. The medial band of the plantar fascia showed an average reduction of 1.45 mm
after the first week, 1.99 mm after four weeks, 2.30 mm at two months and 2.29 mm at
three months. Reductions in thickness were also observed in the central band, however
little change was observed in the lateral band. Six participants experienced a complete
resolution of symptoms after two months. The investigators concluded that PRP should
be considered in the treatment of chronic plantar fasciitis. Although this case study had
several limitations - including but not limited to a lack of controls, a small participant
population and brief follow-up - this study demonstrated a promising use for PRP
treatment for patients with plantar fasciitis (Barrett and Erredge 37).
In 2007, Lee and Ahmad conducted a prospective, randomized, controlled,
observer-blinded study comparing corticosteroid to intralesional autologous blood
injection for patients with plantar fasciitis. Sixty-four participants with symptoms of
plantar fasciitis lasting longer than six weeks were enrolled in the study, however only 61
data sets were complete. The VAS and tenderness threshold were used as primary
outcomes. Participants were assessed at baseline, six weeks, three months and six months
post-treatment.
A significant improvement in VAS and tenderness threshold was observed for
both groups (p<0.05). The corticosteroid group reported significantly lower VAS at six
weeks and three months compared to the autologous blood treatment (MD at six weeks =
-1.7 (95% Cl -3.0 to -0.4); MD at three months - -2.0 (-3.4 to -0.6)(p<0.05)). This
difference was not significantly evident at six months. The corticosteroid group reported
significantly higher tenderness threshold at each follow-up post-injection (MD at six
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weeks = 2.3 (95% Cl 0.9 to 3.7); MD at three months = 2.4 (95% Cl 0.9 to 3.9; MD at six
months = 2.1 (0.6 to 3.6)). The authors concluded that corticosteroid therapy is a superior
therapy in showing a faster time to recovery. Our study will add to the evidence provided
by this study (Lee and Ahmad 984-990).
Currently, Peerbooms et al are conducting a multi-centre randomized clinical trial
to compare the use of PRP to kenacort 40 mg/mL triamcinolon acetonide (corticosteroid)
injection treatment for 120 participants with chronic plantar fasciitis. The PRP will be
administered using a GPS System (Cell Factor Technologies), designed to concentrate the
platelets six- to eightfold from baseline blood sample. All participants will be sent home
with a standardized stretching protocol to complete, beginning 48 hours to two weeks
after injection. Then, participants will maintain a formal strengthening program
maintained for four weeks. The main outcome measures - decreased pain and increased
function - will be assessed at baseline, four, eight, 12, 26 weeks and one year post
treatment. This study will supplement the knowledge obtained from our study and may
also provide more insight into the optimal platelet concentration that is needed to treat
patients with plantar fasciitis (Peerbooms et al 69).
2.11: Conclusions
With the investigation of any new treatment, not only efficacy, but the economical
feasibility must be taken into account. Currently, PRP procedures are not covered by third
party insurance providers. The average system costs $150 per unit, plus clinical expenses.
Clinicians, patients and third party insurance providers may also consider the feasibility
of PRP treatment in comparison to the cost of surgery.
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Not only is feasibility a consideration, but PRP has received media attention as a
means of performance enhancement. Although the World Anti-Doping Agency prohibits
all growth factor therapies in elite sports, the unbound IGF-1 found in PRP is reportedly
subtherapeutic by a factor of 500 and the half-life is too short to exhibit systematic
anabolic effects (Hall et al 602-608). The 2011 World Anti-Doping Agency prohibition
list has removed intramuscular administration of PRP since its effectiveness as a
performance enhancer beyond therapeutic means was not proven (World Anti-Doping
Agency, 2010).
Although the PRP has been shown to be effective in accelerating the healing of
injured tissue, the results from randomized clinical trials examining PRP’s effectiveness
in treating patients with plantar fasciitis are not yet available. Our study will add to the
existing knowledge examining PRP for patients with plantar fasciitis and may provide
evidence of a new treatment for this frustrating condition.
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Chapter 3: Objectives
The primary objective of this study is to determine whether treatment of plantar
fasciitis with autologous conditioned plasma (ACP®) will lead to a greater reduction in
pain and improved function at one year post-treatment compared to participants given the
standard treatment, a corticosteroid injection. We hypothesized that there will be no
significant difference between outcome measurements for participants treated with the
ACP® injection compared to participants treated with corticosteroid injection.
The secondary objective of this study is to assess the effectiveness of ACP® in
improving the overall quality of life compared to corticosteroid injection at one year post
treatment. It was hypothesized that no significant difference between groups would be
found for any of the subjective outcome measures.
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Chapter 4: Methodology
4. 1 Study Design
We recruited 140 participants from primary care clinics in the London region. We
faxed an advertising poster to primary care physicians listed on The College of
Physicians and Surgeons of Ontario website. Eligible participants were over the age of 18
years, able to give informed consent and diagnosed as having painful inner heel pain. We
allocated eligible consenting participants into one of two groups (ACP® treatment or
corticosteroid treatment) using a computer-generated randomization scheme, in permuted
blocks of two and four, with stratification by duration of symptoms (< six months versus
> six months). We treated all participants at the Fowler Kennedy Sport Medicine Clinic
in London, Ontario, Canada.
The only person aware of participant’s group allocation was the registered nurse who
prepared each injection. For the duration of the study, the participant, surgeon and
outcome assessor were blinded to which treatment each participant received. We attained
informed consent from all participants and ethics approval by the Health Science
Research Ethics Board prior to the initiation of this study (Appendix B and Appendix C).
One injection of either Celestone® or ACP® was administered to each
participant. Regardless of treatment group, we retrieved a blood sample from the non
dominant arm of all participants (Figure 4a). For participants in the corticosteroid group,
the sample was taken to assist with blinding. It was discarded rather than used for
injection. For participants in the ACP® group, the sample was used to prepare the ACP®.
The registered nurse retrieved the blood sample and prepared the concealed' injections for

*See Appendix B and C fo r a sample Information and Consent Form and Full Ethics Board Approval
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Figure 4. A. Blood sample withdrawal using the ACP®-DS System. B. Sample after
centrifugation. C. Retrieval of the ACP® sample. D. Prepared ACP® sample E.
2% Xylocaine® and treatment preparation. F. Preparation of the treatment area
with iodine. G. Administration of 2% Xylocaine®. H. Administration of the
treatment.

all participants (Figure 4b-e). The surgeon and outcome assessor were not present at the
time of obtaining the blood sample or preparing the treatment. The orthopaedic surgeon
re-entered the assessment room once the concealed injections had been prepared and
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administered all injections in both groups (Figure 4f-h). The orthopaedic surgeon
suggested all participants complete a three month physiotherapy program.
We injected the participant’s own plasma at the site of injury; nothing was added
to the sample. The registered nurse retrieved a 10-12 mL blood sample using the Arthrex
ABS-10010S Double Syringe with Syringe Cap (ACP®-DS). The blood sample was
separated using a soft spin centrifuge (ROTOFIX32) set to 5 minutes at 1500 rpm/rcf for
each blood sample. Three to four mililitres of platelet rich plasma was pulled into the
smaller syringe followed by concealment of the syringe contents with opaque tape. Four
cc of 2% Xylocaine® was prepared in a separate syringe to numb the injection area to
minimize pain.
As the participant lay supine on the plinth, iodine solution was used to wash the
area. Then the 2% Xylocaine® followed by the ACP® was injected into the medial
calcaneal origin of the plantar fascia, which was the site of maximum tenderness. Care
was taken to avoid injecting 2% Xylocaine® where the ACP® injection was
administered. To do this, the freezing was administered more superficial than the ACP®.
The orthopaedic surgeon administered the ACP® treatment after proceeding past the
point of the Xylocaine® injection.
We administered Celestone® to the participants randomized to the corticosteroid
group. The 10 to 12 mL blood sample retrieved was retained in a vile. The centrifuge was
run for 5 minutes as the participant lay supine to assist with blinding. The registered
nurse prepared two syringes. The first with 2% Xylocaine® as described above. The
second with one cc of Celestone® using a syringe identical to the size of the smaller
syringe used in the ACP®-DS system. Two cc of 2% Xylocaine® was added to the
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Celestone® syringe to equilibrate the weight with the ACP® treatment and ultimately
assist with blinding the orthopaedic surgeon. The syringe with Celestone® was covered
with opaque tape to conceal its contents. Both syringes were presented to the orthopaedic
surgeon in the assessment room. The orthopaedic surgeon administered the freezing,
followed by the injection containing Celestone® at the medial calcaneal origin of the
plantar fascia.
We used primary and secondary outcome measures to assess participant progress.
We gathered baseline values for all participants on the initial visit. Participants were
required to return to the clinic two weeks, six weeks, three months, six months and one
year after the injection for follow-up visits. We asked participants if they had attended
physiotherapy sessions since the previous visit.

4.2 Eligibility Requirements
Eligible participants were between the ages of 18 to 70 years old, able to give
informed consent and diagnosed as having painful inner heel pain. Participants were
required to have a score greater or equal to five on the visual analog scale (VAS) Plantar
Fasciitis Pain/Disability Scale (PFPD) and 30 on the American Orthopaedic Foot and
Ankle Midfoot Society Scale (AOFAS).
Participants were excluded if suffering from tendon rupture, neurological or
vascular insufficiencies in the painful heel, Paget disease or calcaneal fat pad atrophy,
osteomyelitis, fracture of the calcaneus, ankle inflammation, recent infection in the
treatment area, history of rheumatic diseases, collagenosis or metabolic disorders,
immunosuppressive therapy or coagulation disturbance and/or therapy, long-term
treatment with corticosteroids, previous surgery of heel, malignant disease, diabetes
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mellitus, severe cardiac or respiratory disease, significant abnormalities in hepatic
function or participation in another clinical study for the treatment of plantar fasciitis at
the same time.
4.3 Outcome Measures (Appendix E)
The primary outcome measure we used was the region-specific AOFAS. The
AOFAS contains both a subjective participant reported section and an objective surgeon
assessed section. The survey is scored by taking the sum of all questions. The scores
range from zero to 100. A score of 100 represents the best possible outcome and a score
of zero represents the most disabled participants with the most painful plantar fasciitis
(Ibrahim et al. 65-74). This region-specific instrument was chosen as the primary
outcome measure because it has demonstrated test retest reliability, validity, sensitivity to
change and responsiveness for conditions of the foot and ankle. A minimally important
change was considered to be at least a five point change with an effect size of 0.59
(Ibrahim et al. 65-74; Dawson et al. 918-931).
The secondary outcome measures were the PFPD and SF-12. The PFPD contains
a pain VAS, which is commonly used to assess pain (Willis et al. 3-9). The creators of the
disease-specific PFPD claim validity and reliability by comparing related sections with
the Foot Function Index (FFI) and VAS. The minimally important difference of the 100
mm VAS scale has been shown to be nine mm (Landrof and Radford 15-19). The SF-12
is a well-known generic assessment for quality of life (Gandek et al. 1171-1178). For all
outcome measures, we used an effect size of 0.5 to represent the minimally clinically
important difference (MCID) (Guyatt, Walter and Norman 171-178).
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4.4 Sample Size
The sample size of 64 participants per group was calculated based on the ability to
detect a moderate effect size of 0.5 with 80% statistical power and 0.05 type one error.
The sample size was adjusted to account for a 10% drop-out rate, yielding 70 participants
per treatment group.
4.5 Statistical Analysis
For all outcome measures, an effect size of 0.5 was used to determine the
minimally clinically important difference (MCID) (Guyatt, Walter and Norman 171-178).
We presented adjusted means for each group, mean difference with 95% confidence
intervals and associated probability values. Participants were analyzed using intention-totreat (ITT). Participants that drop out of the study at any time point were included in the
analysis using the last outcome carried forward method (LOCF).
To analyze the primary outcome, we used an analysis of covariance (ANCOVA).
The dependent variable was the AOFAS score at one year post-treatment, the
independent variable was the treatment group and the covariate was the baseline AOFAS
score. The same analysis was used to analyze the secondary outcomes.
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Chapter 5: Results
5.1: Participant Flow
Twenty-two physicians from the London region forwarded potential participants.
Fourteen of the 22 were general/family physicians, four were sports medicine physicians,
two were orthopaedic surgeons and two specialized in emergency medicine.
The participant flow throughout the trial is summarized in Figure 5. Of 29
participants assessed for eligibility, three failed to meet the eligibility criteria or had not
explored conservative treatment. These participants were excluded from the trial.
Currently, 26 participants have given consent and are enrolled in the study. Fourteen
participants are allocated to the ACP® group and 12 participants are allocated to the
corticosteroid group. After three months, one participant withdrew from the study to
receive an additional injection. These analyses include the two, six and 12 week data of
14 randomized participants, seven in the ACP® group and seven in the corticosteroid
group.

5.2: Baseline Demographics and Participant Characteristics
The baseline demographics and characteristics of are similar between groups for
gender, age, height, dominant side, previous treatment, duration of symptoms, baseline
medications, employment status, employment type, reduced hours of work and smoking
habits. The AOFAS, SF-12 and PFPD had similar baseline scores between groups (Table
2).
There were two participants with bilateral plantar fasciitis who were allocated to
the ACP® group. The ACP® group had a greater proportion of participants that were
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engaged in activities of daily living at the onset of symptoms compared to the
corticosteroid group (50% versus 25%, respectively); and the corticosteroid group had a
greater proportion that were at work at the onset of symptoms (25% versus 7.14%,
respectively) (Table 2).
5.3.1: Data Analysis
Descriptive baseline outcome scores for the 14 participants assessed up to three
months are presented in Table 3. LOCF was used to fill in missing six-week follow-up
scores for one participant who was allocated to the corticosteroid group and three-month
follow-up scores for one participant who was allocated to the ACP® group who missed
their follow-up.
5.3.2: Primary Analysis
To assess reductions in pain and improvement in function at 3 months, a repeated
measures ANCOVA was used to analyze AOFAS scales controlling for baseline scores.
Fourteen participants were included in the analysis. In the ACP® group, the adjusted
means 68.4 ± 3.8 (mean ± standard error) at two weeks 68.5 ± 3.8 at six weeks and 67.7 ±
3.7 at three months were used to calculate between group differences. In the
corticosteroid group, 63.0 ± 3.8, 69.8 ± 3.8 and 72.2 ± 3.7 were the adjusted means used
in the analysis for two weeks, six weeks and three months, respectively. No statistically
significant differences were found between follow-up visits and treatment groups (p >
0.05) (Table 4). Baseline AOFAS midfoot scores do not appear to be a significant
predictor of follow-up scores (p>0.05).
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Figure 5 Participant Flow throughout the Trial
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Table 2 Participant Demographics and Baseline Characteristics
Characteristic
ACP® (n = 7)
Sex, n (%)
Male
2 (28.6)
50.7 ± 14.2
Age, mean ± SD (years)
175.3 ±7.6
Height, mean ± SD (centimeters)
200.6 ± 40.9
Weight, mean ± SD (lbs)
Affected foot, n (%)
Right
3 (42.9)
Left
2 (28.6)
Both
2 (28.6)
Dominant Foot, n (%)
Right
4(57.1)
Prior Treatment, n (%)a
Physical Therapy
4(57.1)
Orthoses
4(57.1)
Custom
4 (100.0)
Over the Counter
0(0)
Taping or heel pads
4(57.1)
Shoe modification
2 (28.6)
Night splints
3 (42.9)
Topical analgesics/anti-inflamm. gels
1 (14.3)
Prescription analgesics or NSAIDs
3 (42.9)
Local anesthetic injections
0(0)
Electrocorporeal Shockwave Therapy
1 (14.3)
Surgery
0(0)
Corticosteroid
1 (14.3)
Other
0(0)
Duration of symptoms, median (range)
14.7 (10.5, 74.5)
(months)
Activity at Onset, n (%)
Activities of daily living
3 (42.9)
Work
0(0)
Sport
3 (42.9)
No specific injury recalled
1 (14.3)
Baseline Medications, n (%)
NSAIDs
2 (28.6)
Pain killers
1 (14.3)
Narcotics
3 (42.9)
Employment Status, n (%)
Full-time
3 (42.9)
Part-time
2 (28.6)
Stay-at-home parent
0(0)
Student
0(0)
Retired
0(0)
Unemployed/Social Assistance
1 (14-3)_________

Corticosteroid (n = 7)
1 (14.3)
50.1 ±7.8
157.8 ±11.5
150.1 ±13.7
5(71.4)
2 (28.6)
0(0)
6 (85.7)
5(71.4)
5(71.4)
5 (100.0)
0(0)
5(71.4)
3 (42.9)
4(57.1)
2 (28.6)
2 (28.6)
0(0)
2 (28.6)
0(0)
3 (42.9)
2 (28.6)
12.0 (5.5, 75.93)

1 (14.3)
3 (42.9)
2 (28.6)
1 (14.3)
3 (42.9)
2 (28.6)
1 (14.3)______________
3 (42.9)
2 (28.6)
0(0)
1 (14.3)
1 (14.3)
0(0)________________
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Characteristic
Volunteer
Other
Employment Type
Prolonged Standing
Desk Job
Other
Employment Hours Reduced
Yes
No
N/A
Off-Work Unrelated to Plantar Fasciitis
Employment Duties Modified
Yes
No
N/A
Smoking History
Yes

ACP®(n=7)
0(0)
1 (14.3)

Corticosteroid (n=7)
0(0)
0(0)

6 (85.7)
0(0)
1 (14.3)

5(71.4)
2 (28.6)
0(0)

1 (14.3)
5 (71.4)
1 (14.3)
1 (14.3)

2 (28.6)
4(57.1)
1 (14.3)
1 (14.3)

1 (14.3)
5(71.4)
1 (14.3)

3 (42.9)
3 (42.9)
1 (14.3)

2 (28.6)

2 (28.6

Abbreviations: SD = standard deviation, N S A ID s - non-steroid anti-inflammatory agents.
P articipants were permitted to select more than one previous treatment and baseline medication.
Percentages are not required to sum to 100.

Table 3: Outcome Measures Descriptive Statistics
n
Baseline
AOFAS (unadjusted mean ± SD)
ACP®
7
51.4± 12.1
Corticost.
7
56.6 ± 13.5
SF-12 PCS (unadjusted mean ± SD)
ACP®
7
42.7 ±9.8
Corticost.
7
38.6 ± 11.8
SF-12 MCS (unadjusted mean ± SD)
46.2 ± 10.6
ACP®
7
Corticost.
7
50.6 ± 14.4
PFPD (unadjusted mean ±SD)
ACP®
7
66.7 ± 13.5
Corticost.
7
62.6 ± 13.3
Attended Physiotherapy (n, %>)
N/A
ACP®
7
Corticost.
7
N/A

2vvk

6wk

3months

66.6 ± 12.1
64.9 ± 14.3

67.0 ± 12.3
71.3 ± 11.7

65.9 ± 10.8
74.0 ± 14.8

45.8 ±4.2
45.1 ± 13.0

43.8 ±7.6
48.3 ±9.8

44.5 ± 7.4
46.0 ± 16.6

46.6 ±6.8
49.3 ± 7.9

45.4 ± 10.4
46.7 ± 9.2

46.7 ± 10.8
49.4 ± 12.1

59.8 ± 12.3
51.7 ± 17.2

54.5 ± 14.7
40.1 ±20.2

56.0 ± 13.3
35.4 ±21.5

3 (42.9)
1 (14.3)

4(57.1)
1 (14.3)

5(71.4)
3 (42.9)
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5.4.3: Secondary Analysis
To analyze our secondary objective, an ANCOVA was used to assess
improvements in overall quality of life (SF-12 scores) between treatment groups
controlling for baseline scores. Separate ANCOVAs were conducted to analyze the
physical component summary scale (PCS) and mental component summary scale (MCS)
of the SF-12.
The adjusted means used to analyze the PCS portion were 44.4 ±2.1 at two
weeks, 42.4 ± 1.5 at six weeks and 42.6 ± 3.1 for the ACP® group. For the corticosteroid
group, 46.6 ±2.1 at two weeks, 49.8 ± 1.5 at six weeks and 47.9 ± 3.0 were used as
adjusted means. The mean between-groups difference was not statistically different
between treatment groups at any time point (p>0.05). The baseline PCS scores do not
appear to be a significant predictor of follow-up scores (Table 4).
The adjusted means used in the ANCOVA analysis of the MCS were 47.6 ± 1.8 at
two weeks, 46.8 ± 2.4 at six weeks and 48.4 ± 2.4 at three months for the ACP® group.
For the corticosteroid group, adjusted means were 48.3 ± 1.8 at two weeks, 45.3 ± 2.4 at
six weeks and 47.7 ± 2.4 at three months. The mean between-groups difference was not
statistically different between groups, (p>0.05) at any time point. The baseline MCS
scores do not appear to be a significant predictor of follow-up scores (Table 4).
5.4: Physiotherapy
Nine of 14 participants attended physiotherapy during the first three months.
Three participants in the ACP® treatment group and one participant in the corticosteroid
group attended physiotherapy within two weeks after injection. At six weeks, four
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participants in the ACP® and one participant in the corticosteroid group attended
physiotherapy since the previous visit. At three months, four participants in the ACP®
group and three participants in the corticosteroid group had attended since their previous
visit (Table 3).
Table 4: Between-Group Differences for Outcome Measures.
2 Weeks Post-injection
Outcome Measure ACP® (n=7)a Cortic. (n=7)a
Difference (95% Cl)
AOFAS-midfoot
68.4 ±3.8
63.0 ±3.8
5.4 (-6.7, 17.5)
SF-12 PCS
44.4 ±2.1
46.6 ±2.1
-2.2 (-8.9, 4.4)
SF-12 MCS
47.6 ± 1.8
48.3 ± 1.8
-0.7 (-6.5, 5.0)
PFPD
57.7 ±2.5
53.8 ±2.5
3.9 (-3.8, 11.6)
6 Weeks Post-injection
ACP® (n=7)a Cortic. (n=7)a
Difference (95% Cl)
AOFAS-midfoot
68.5 ±3.8
69.8 ±3.8
-1.3 (-13.2, 10.6)
SF-12 PCS
42.4 ± 1.5
49.8 ± 1.5
-7.4 (-12.3, -2.5)
SF-12 MCS
46.8 ±2.4
45.3 ± 2.4
1.5 (-6.0, 8.9)
PFPD
52.2 ±3.8
42.4 ±3.8
9.8 (-2.1, 21.7)
3 months post-injection
ACP® (n=7)a Cortic. (n=7)a
Difference (95% Cl)
AOFAS-midfoot
67.7 ±3.7
72.2 ±3.7
-4.6 (-16.3,7.2)
SF-12 PCS
42.6 ±3.1
47.9 ±3.0
-5.3 (-14.9, 4.4)
48.4 ±2.4
SF-12 MCS
47.7 ± 2.4
0.6 (-7.0, 8.3)
PFPD
53.5 ±3.0
37.9 ±3.0
15.6 (6.2, 24.9)

P value
p=0.35
p=0.48
p=0.78
p=0.29
P value
p=0.81
p=0.01
p=0.67
p=0.10
P value
p=0.41
p=0.25
p=0.86
p=0.00

♦D enotes statistical significant, p<0.05
aAdjusted means ± standard error, mean differences (95% confidence intervals [C l]), P values presented for
com parisons at 2 w eeks, 6 w eeks and 3 months post-injection
Abbreviations : C l = C onfidence Interval; A O FA S-m idfoot = A m erican Orthopaedic F oot and Ankle
M idfoot Society Scale; SF-12 PCS = SF-12 Health Survey Physical Component Summary Scale; SF-12
M CS = S F-12 Health Survey Mental Component Summary Scale; PFPD = Plantar Fasciitis Pain/Disability
Scale
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Chapter 6: Discussion
The objectives of this study were to determine whether treatment of plantar
fasciitis with ACP® leads to reduced pain, improved function and improved quality of
life at one year post-treatment compared to the standard corticosteroid injection. We
present the results of an interim analysis of 14 participants with follow-up three months
post randomization. We did not observe a significant difference between AOFAS or SF12 scores. At three months, these findings are consistent with our null hypothesis, which
states that there will be no difference between treatment options assessed by participant
completed subjective outcome measures analyzed at one year.
At the time of this interim analysis, all of the outcome measures demonstrate
consistent findings. Since the interim analysis only consisted of 14 of the 140 participants
required to properly power this trial, our ability to draw definitive conclusions from the
data is extremely low at this time. The clinical effectiveness of either treatment cannot be
determined at this point.
Our findings are in contrast to a study by Barrett and Erredge, who reported that
six of nine participants experienced complete resolution of symptoms after two months.
This study monitored plantar fascia thickness using ultrasound and demonstrated a
decrease in plantar fascia thickness within one week of PRP injection. In our interim
analysis, according to the AOFAS scale, two participants in the corticosteroid group and
one participant in the ACP® group were pain free at three months. Unlike our study,
Barrett and Erredge lacked a comparison group and validated subjective outcome
measures (Barrett and Erredge 37).
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In the randomized, controlled, observer-blinded study by Lee and Ahmad (2007).
Using a 10 mm pain visual analog scale (VAS) and tenderness threshold for 64 enrolled
participants, the corticosteroid group had significantly lower pain at six weeks and three
months; and significantly higher tenderness threshold at all follow-ups compared to the
PRP group (Lee and Ahmad 984-990). The findings of our study may parallel those of
Lee and Ahmad, but greater precision will come with greater power as more participants
complete the study.
Thus far, participants enrolled in our trial have not experienced adverse events.
This may reflect the safety of both treatments for patients with plantar fasciitis. The
number of injections and time between corticosteroid injections were monitored by an
orthopaedic surgeon. Therefore, the potential for complications linked to successive
corticosteroid injections appears to be successfully minimized (Kenneth and Anderson
427-434; Roxas 83-93; Yucel et al 105-110; Tatli and Kapasi 3-9; Neufeld and Cerrato
338-346).
Limitations of our study include the small sample, resulting low power and
inability to make definitive conclusions at this interim analysis, variability in frequency
of visits to physical therapy and failure to standardize the physical therapy protocol. In
our study, participants were asked to attend physical therapy, but a standardized program
was not provided and compliance with our recommendation was not heavily monitored.
Our decision not to standardize the physical therapy regimen was based on our perception
that different underlying mechanisms are thought to contribute to chronic symptoms
(Roxas 83-93; Neufeld and Cerrato 338-346; Tatli and Kapasi 3-9; Thomas et al S I-19).
The number of visits per week to the physiotherapy clinic since each participant’s last
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follow-up was recorded. At three months, five of seven participants in the ACP® group
and three of seven participants in the corticosteroid group had attended physiotherapy at
least one time since their previous visit.
Although our intention was to sample a group of participants representative of the
population with plantar fasciitis, it is possible that we were unsuccessful. First,
representativeness depends on whether patients with plantar fasciitis seek treatment at a
sport medicine facility. Since plantar fasciitis affects patients from months to years,
patients may not seek help from the family physician, may be currently undergoing
treatment at the physical therapy, podiatry, massage therapy clinic etc., or may not seek
treatment at all since many of the treatment options are not covered by health insurance.
Second, representativeness depends on the primary care physicians’ remembering to refer
their patients to our study. (Roxas 83-93; Neufeld and Cerrato 338-346; Thomas et al
Sl-19).
The representativeness of our study could also have been affected by imbalances
in potentially prognostic characteristics. For example, in our study, only 15 of 26
participants had attended physical therapy before presenting to the surgeon. Moreover,
highly motivated participants may appear to have more effective treatment outcomes due
to their willingness to perform at home exercises, in addition to the effect of the
corticosteroid or ACP® injection. However, since this is a randomized trial, potentially
prognostic characteristics should balance out between groups once the number of
participants who complete the study increases such that any confounding factors will
influence both treatment groups in the same manner. At this time, with only 14
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participants included in our examination of between-group characteristics there are
differences in the number of participants with bilateral heel pain and activity at onset.
Strengths of this study include its methodological design. Participants were
randomized into treatment groups after their eligibility was fully determined. This feature
reduces the risk of selection bias and the risk of an imbalance in prognostic factors
between groups. We also took great pains to blind the outcome assessor and participant
by drawing blood and centrifuging the sample for all participants regardless of group
allocation. This feature will serve to equalize any placebo effect and any measurement
bias. We also performed an intention-to-treat analysis, which preserves the integrity of
the randomized groups, preserving the overall validity of the trial. We used the lastoutcome-carried-forward approach to replace missing end-point data, which is a
conservative means of imputing missing values to prevent an inflation of the Type I error
rate (Guyatt et al. 995-998; Guyatt et al. 2008).
For future studies, it may provide supplementary information if the level of
cellular activity at the site of injection is measured. Since an activation agent is not
included in the ACP® system, the degranulation of platelets is dependent on activation
by damaged collagen alone. An activation agent may have increased the probability of
degranulation once the injection was administered. In our study, it was not possible to
determine if the platelets were successively activated, which would influence the
potential for accelerated healing (Arthrex Research and Development; Fufa et al 684-690;
Hall eta l 602-608).
Although PRP has shown to be effective in accelerating healing in preliminary
studies, the optimal concentration of platelets, method of preparation, use of an activating
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agent, etc. are yet to be determined. Four times the platelet concentration is considered to
be clinically effective; however the Arthrex System has been reported to concentrate the
sample two to three times the original amount (Arthrex Research and Development; Hall
et al 602-608). Thus, it may not have reached the threshold concentration of platelets
required to accelerate healing at the injury site.
To investigate the appropriate combination of treatments for optimal benefit, it
would have been useful to record concomitant treatment and changes in treatment
throughout the study. Participants were permitted to continue concomitant treatment, as
the standard treatment for plantar fasciitis generally suggests a combination of options. It
may be that participants that reported the most benefit had the optimal combination of
treatments throughout the study (Neufeld and Cerrato 338-346; Thomas et al SI-19).
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Chapter 7: Conclusion
At this time, this study is inconclusive as to the effectiveness of ACP® compared
to corticosteroid for the treatment of plantar fasciitis. Participants appear to tolerate the
injection well. There are no adverse events to date.
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Appendix A: GLOSSARY OF TERMS
angiogenesis: growth of new blood vessels from pre-existing vasculature
Autologous Conditioned Plasma (ACP®): ACP® involves taking a blood sample from
the patient, isolating the platelets and injecting them back into that patient at the
injury site. It is a novel treatment that may accelerate the healing of injured tissue.
bilateral pain: pain affected both limbs
blinding: concealing the treatment the participant will receive
botulism toxin A injections: trade name Botox, derived from the bacterium Clostridium
botulinum. Results in decreased muscle activity and contraction by preventing the
release of Acetylcholine from its storage vesicle within the end-terminal of a
neuron.
centrifuge: machine that will spin a liquid sample down into separated layers based on
density
corticosteroid injection: an anti-inflammatory agent that is traditionally used for short
term pain relief
intention-to-treat (ITT): a conservative method of data analysis where participants are
analyzed in the treatment group they were allocated to, regardless of the actual
treatment they received
last outcome carried forward method (LOCF): a conservative method in data analysis
where the participant’s outcome measure score from the last visit before drop out
is used to complete the data set.
mitogenesis: natural process which results in an increased number of cells
non-steroid anti-inflammatory drugs (NSAIDs): medication primarily used to treat
inflammation. For example, Acetylsalicycle acid (Aspirin).
orthosis: device the correction the alignment and function of a limb
physiotherapy: In regards to plantar fasciitis, the goal of physiotherapy treatment should
be to optimize tension of the fascia during walking gait in order to prevent long
term strain(Roxas 83-93). To help alleviate symptoms, stretching of the muscles
originating at the volar calcaneus - the abductor digiti minimi quinti, digitorum
brevis, quadrates plantae, and adductor hallucis - will lead to the release of
muscle tightness. Stretching therapy as a treatment originates from the idea that
overloading of the plantar foot muscles can lead to symptoms in the plantar fascia
(Tatli and Kapasi 3-9).
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plantar fascia: a fibrous sheet of connective tissue that supports the foot arch and acts as
a shock absorber for the foot and leg (Roxas 83-93). The thicker, central portion
of the plantar fascia spreads into five digital bands at the metatarsophalangeal
joints and is flanked by thinner, lateral and medial portions. The plantar fascia is
essentially inelastic, having a maximal change in elongation of 4%. In
dorsiflexion, such as during the toe-off phase of walking gait, a high tensile force
is concentrated at the origin of the plantar fascia. This may be a predisposition to
the development of this disease. This process was termed the “windlass
mechanism” by Hicks (Neufeld and Cerrato 338-346; Tatli and Kapasi 3-9).
plantar fasciitis: characterized as a degenerative process of the plantar fascia that
manifests clinically as inferior heel pain concentrated at the anteromedial aspect
of the calcaneus.
platelets: a central player in the immune response, involved in clotting, inflammation and
the wound healing response.
Platelet Rich Plasma (PRP): a treatment that involves taking a sample of a patient’s
own blood, altering the sample to be high in platelet concentration and injecting it
at a wound site in order to accelerate the healing response.
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Office of Research Ethics
The University of Western Ontario
Room 5150 Support Services Building, London, ON, Canada NBA 3K7
Telephone: (519) 661-<3036 Fax: (519) 650-2496 Email: £hlcs@uwo cs
Website: wmv.uwo.caftesearcWelhtcs

Use of Human Subjects - Ethics Approval Notice
Principal Investigator: Or. K.R Whitts
Review Number: 16901
Review Date: December 17.2010

Review Level: Expe&Bd
Revision Number: 2
Approved Local S o f Participant».' 140

Protocol Title: A RondonVzeci Double-Blind Critical Trtaito investigate the Use c f Auiotagwu*
Conditioned Plasm* <ACP) tor Patxjnl»

Ih Plantar Fascllti*

Department and Institution: Surgery. University of Western Ontario
Sponsor:
Ethics Approval Date: January CM. 2011
Expiry Oats; March 31,2015
Documents Reviewed and Approved: Revised «Mdjsion criteria Revised Advemsoment.
Documents Received for Inform ation:
This is to notify you that The University of Western Ontario Research Killies Board tor Health Sciences Research Involving Human
Subject* (HSREB) which isocgarmed and operates according to (he Tri-Council Policy Statement. Ethical Conduct of Research
Involving Humans and the Health CanwWlCH Good Clinical Practice Practices’ Consolidated Guidelines, Brxl the applicable laws
and regulations o f Ontario hns reviewed and granted approve! to the above referenced revisions) or amendnucm<s) on the approval
date nixed above. The membership of this KHfi also complies with the membership requirements for REB s os defined in Division 5
o f ihe Food and Drug Regulations.
The ethics approval for this study shell remain valid umil the expiry date noted above assuming timely and acceptable responses to ihe
HSRFTVs periodic requests for surveillance and monitoring information. If you require an updated approval notice prior Ipthat time
you must request It using the UWO Updnted Approval Request Form.
During the course of the research, no deviations from* or changes to, the protocol or consent form may be initiated without poor
written approvnl from the HSRER except wtien necessary to eliminate immediate hazards in (lie subject or when die change;*} involve
onto logistical or administrative aspects o f (be study (c.g. change o f monitor, telephone number). Expedited review of minor
changes) in ongoing studies will be considered. Subjects must receive a copy of (he signed ir.formalvon.'cpnscnt doemnemation
Investigators must promptly also report to die HSRU&:
a) changes Increasing die risk to (he participants} andtor affecting significantly the conduct of the study;

b) all adverse end unexpected experiences or events (had are both serious and uns xpcctcd;
c) new toioemunvon that may adversely affect the safety of the subjects or the conduct of the study.
If these chnngei/advcrsc events require &change to ihe infomnationtoociaem documentation, and/or recruitment advertisement, the
newly revised informationtconsent documentation, and/or advertisement, musi he submitted to this office for approval
Member* of Lhe KSREB who are named as Investigators in research studies, or decline a conflict of interest, da mr. participate in
discuss loai related to, nor vote on. such studies when they are presented to the HSREB.
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LAWSON HEALTH RESEARCH INSTITUTE
FINAL APPROVAL NOTICE
RESEARCH OFFICE REVIEW NO.: R-10-264
PROJECT TITLE: A Randomized Double-Blind Clinical Trial to Investigate the Use of
Autologous Conditioned Plasma (ACP) for Patients wtlh Plantar Fasciitis

PRINCIPAL INVESTIGATOR:

Dr. Kevin R, Willlti

DATE OF REVIEW BY CRIC:

June 22,2010

I lealth Sciences REB#:

16901

Please be advised that the above project was reviewed by the Clinical Research Impact
Committee and the project:

Was Approved

PLEASE INFORM THE APPROPRIATE NURSING UNITS,
LABORATORIES, ETC. BEFORE STARTING THIS
PROTOCOL. THE RESEARCH OFFICE NUMBER MUST BE
USED WHEN COMMUNICATING WITH THESE AREAS.
Dr. David Hill
V.P. Research
Lawson Health Research Institute
AUjuture correspondence concerning ¡his study should include the Research Office Review
Number and should be directed to Sherry Paiva, CRIC Liaison, LHSC, Rm. C2J0, Nurses
Residence, South Street H ospital

oc: Administration
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Appendix C: Letter of Information/Letter of Consent

o ' »FO W LER
> ¿ ^K E N N E D Y
LE T T E R OF INFORMATION
Title of R esearch ;
A Randomized Double-8 ind Clinical Trial to Investigate tie Use of Autologous
Conditioned Plasma (ACP) for Patents wifi Plantar Fasciitis
Lead R esearch ers:
Dr. Kevin W ills
Fowler Kennedy Snorts Medicine Clinic. The University of Western Ontario.
London, Ontario.
Dr. David Sanders
London Hea th Sciences Centre, Victoria Hospital. Room E4-123
London, Ontario,
Dr. Dianne Bryant
Eibom College, The University of Western Ontario
London , Ontari

Information:
You are being invited to participate in a research study to compare the effectiveness of
a new injection treatment to the standard injection treatment for plantar fasciitis. The
new treatment is called Autologous Conditioned Plasm a (ACP) injection, which involves
removing a blood sample (approximately 4 teaspoons) from your arm. separating a
component of the blood called the plasma, and injecting the plasma into your foot at the
site of the pain. The reason this treatment may work is that plasma contains platelets,
which release growth factors that may acce erate the healing process. The usual
injection treatment is corticosteroid, which has been shown to relieve pain in some
patients.
The objective of this study is to determine whether the A CP injection will reduce pain
and improve function and qua ity of life compared to a corticosteroid injection. In order
to determine whether A CP injection is better than a corticosteroid injection, we must
randomize (like Hipping a com) you to one of these injections One hundred and forty
(140) patients, 70 per group, will participate in this study.

1of 6 | iP-a§e
Versio n ; April 13, 2010

Patient Initials:
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Pro cedu res:
All patients between the ages of 18 and 70 who have inner heal pain or a diagnosis of
plantar fasciitis wil be invited to take part in this study.
If you decide to participate in this study, approximately four teaspoons of blood will be
removed torn your non-dominant arm by a nurse within two weeks of your initial
appointment. The blood will be placed into a machine that will spin the blood and
separate it into components, so that the plasma can be isolated for the AGP injection, if
you are part of the A GP injection treatment group, the AGP will be injected at the site of
maximum tenderness on your inner hee If you are part of the corticosteroid treatment
group, the blood sample will be discarded and the inner heel will be injected with a
cart costeroid named celestone instead of AGP.
You will not be told which injection you receive unit the end of the study because
knowledge of treatment group has been shown to influence results in previous clinical
studies.
—
The orthopaedic surgeon will recommend that you attend physiotherapy for three
months. W e will then ask you to return for standard follow-up visits with your surgeon at
intervals of 6 weeks, 3 months, € months and 12 months after your initial visit. At each
visit you will be asked to complete three questionnaires and the surgeon will evaluate
the condition of your pantar fasciitis. These follow-up visits will take less than an hour.
Patients who have difficulties fo lowing study treatment can consul their physician for
alternative treatment options.
Alternatives to Participation:

If you do not choose to participate in this study, you will receive the usual care for patients
who have plantar fasciitis which may include an injection of ccrfcooid steroid and/or
physiotherapy.
R isk s:
There are no additional risks outside the standard of care to participants of this study.
With any injection you risk infection. Both the surgeon and nurse are trained to follow
proper sterilization procedures to minimize these risks. The data that is collected from
you Is protected by a username and password. It travels in a scrambled format to a
server (storage computer) that is located in Toronto. The company that houses the
server Is a professional company with extremely high standards of physical and virtual
security. We want to let you know however, that even with this high level of security,
there is always a remote chance that your information could be accessed or ‘hacked* by

2of§ | P a s *
Version: April 13, 2Q10
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someone who is not supposed to have your information. If we became aware that this
had happened, we would Inform you immediately.
Benefits:
There may be no direct benefit to you by participating in this study: however your
participation will help inform clinicians a s to which injection treatment offers patients with
plantar fasciitis the best outcome.
Cost/Com pensation:
You will not be required to pay for parking if you participate in this study.
Voluntary Participation:
Your participation in this study is voluntary.

You may refuse to participate, refuse to

answer any questions or withdraw from the study at any time with no effect on your
future care Should you choose to withdraw from this study, we will keep all data
obtained up to the point that you chose to withdraw.
Participation in this study does not prevent you to m participating in any other research
studies at the present time or future. If you are participating in another research study,
we ask that you p ease inform of us of your participation. You do not waive anylegal
rights by signing the consent form.
Request for Study R esu lts:
Should you decide to participate and want to receive a copy of the study results, please
provide your contact information on a separate piece of paper. Once the study has
been published, a copy will be mailed to you. Please note that the results of this study
are not expected for at least 5 years. Should your mailing information change, please
let us know.
Confidentiality:
All informal on will be kept in strict confidence. Upon agreeing to participate in this
study, you w II be assigned a unique number that will be used for all your information
and data collection. Data that is collected will be username and password protected
and stored on a server located in Toronto through a scramb ed format. Your Identifying
information will not appear on the database used to analyze data. In any pub ¡cation,
presentation or report, your name will not be used and any Information that discloses
your identity will rot be released or published.

3of 6 | P i | e
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Representatives of The University of W estern Ontario Health S cie n ce s R esearch Ethics
Board m ay require a c c e s s to your study re ated records or may folio*’ up with you to
monitor the conduct of the study.

Q uestions:
If you have questions about the conduct of the study or your rights as a research
participant,
Institute

you

m av contact Dr. David Hi I. Scientific Director. Lawson Health R esearch

If you have questions or concerns about your surgery or physiotherapy, please contact
your orthopaedic surgeon or physiotherapist if von have anv nuestinns ahnut this
research, please contact Lyndsay Q ’Brecht
Dianne

or Dr.

Bryant at

- your

orthopaedic surgeon.
This letter is yours to keep.
Sincerely,

Dr. Kevin W il t s . MD, F R C S C
Dr. David Sanders. MD, F R C S C
Dr. Dianne Bryant, PhD
Lyndsay O ’Brecht, M .Sc (can.)

4 of 6 | ? a § e
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«'I'I
vT

«FO W L E R
) t '' KENNEDY

C O N S E N T FO RM
Title of R e se a rch :
A Randomized Double-8 ind Clinical Trial to Investigate the U se of Autologous
Conditioned Plasm a (ACP) for P aten ts with Plantar Fasciitis

I have read the letter of inforntafon, have had the nature of the study explained to mef
and I agree to particpate in the study. All questions have been answered to my
satisfaction.

Prnted Name of

Signature of

the Participant

the Participant

Printed Name of person
resp o n sive for obtaining
informed consent

5 of 6 I ? a f e
Version

April

Date

Signature of person
responsiWe for obtaining
informed consent

Patient
13,

2015

Date

initials:
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□

I would like to receive a copy of the results of this study.
Please mall to:

Patient initials:
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Appendix D: Copyrighted material permission

Figure 1
Subject: Re: Homepathic Treatment for Plantar Fasciitis
To: Lyndsay O'Brecht
I am the publisher.

Date: 11/11/10 03:55 PM
From: Sanjib Sarkar

On Thu, Nov 11, 2010 at 3:07 PM, Lyndsay O'Brecht wrote:
Thank you so much for your quick and kind response. I actually need permission from
the publisher. Can you point me in the right direction????
Thanks again,
Lyndsay

On 11/11/10, Sanjib Sarkar wrote:
I wrote the article. You can use the information with my consent.
Thanks,

On Thu, Nov 11, 2010 at 2:38 PM, Lyndsay O'Brecht wrote:
Hello:
I am a Master's student at the University of Western Ontario. I am currently preparing my
thesis and found an image on the page:
http://blog.hmedicine.com/homeopathv-and-homeopathic-medicineblog/bid/12642/Homeopathv-Treatment-For-Plantar-Fasciitis
that I would love to use in providing background information on plantar fasciitis. I
noticed the material is copyrighted so I am inquiring to know if you could direct me
toward who to contact to obtain consent to use the image.
Thank you,
Lyndsay
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Figure 2
Subject: Re: Permission to use muscles of the foot picture
To: Lyndsay O'Brecht

Date: 11/26/10 10:08 AM

Sorry to be so late in replying to your request, Lyndsay but have been on the
road. Please feel free to use whichever images you need. I hope this isn't to late
for you. Best of luck on your thesis work.
Dr. Wesley Norman
Figure 3
Subject: ACP® study
To:
Dear Lyndsay,
This is no problem what so ever.
Best of luck in you master's endeavors.
Regards,
Josh
Josh Kames
Manager, Research and Development
Arthrex Inc

Serene Stash
Supervisor, Telecommunications
Arthrex, Inc.
-----Original Message----From:
Sent: Thursday, November 11, 2010 12:11 PM
To: Serene Stash
Cc: Webmaster
Subject: Contact_Us_English_ Form Submission Results

Name: Lyndsay O'Brecht
Company: University of Western Ontario

Date: 11/12/10 04:10 PM
From: Josh Kames
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Message Category: Research
Message: Hello:
I am a M.Sc. candidate that is involved in a randomized clinical trial funded by Arthrex
Incorporated through the Fowler Kennedy Sport Medicine Clinic in London, Ontario.
The title of the project is "A Randomized Clinical Trial to Investigate the Use of
Autologous Conditioned Plasma (ACP®) for Patients with Plantar Fasciitis".
One of the requirements as a student of the University of Western Ontario is to write a
thesis summarizing the results of the experiment that were completed during my time in
the program. I was hoping to use a diagram provided by the Arthrex to supplement my
description of the clinical trial.
Specially, I am inquiring whether I may use a figure named "Figure 1 Steps in production
of ACP® using double syringe system" taken from the article called "Autologous
Conditioned Plasma Double Syringe System" by Arthrex Research and Development.
Thank you for your time and consideration,
Lyndsay
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Appendix E: Selected Case Report Forms
ACP® Plantar Fasciitis
Screening Form
Reasons for exclusion from study participation (Check all that apply)
* If yes is checked for any of the exclusion criteria, this patient is not eligible for
participation.
Yes No
(^ ) Ç'jt 1. Tendon rupture, neurological or vascular insufficiencies in the painful heel
(^ ) Ç jj 2. Paget disease or calcaneal fat pad atrophy
(^ ) Ç jj 3. Fracture of the calcaneus
Ç j) ifj) 4. Ankle inflammation
(~Jj ifj) 5. Recent infection in the treatment area
(^ ) Ç j) 6. History of rheumatic diseases, collagenosis or metabolic disorders,
immunosuppressive therapy or coagulation disturbance and/or therapy
(^ ) Ç j) 7. Long term treatment with corticosteroids
(^ ) Ç j) 8. Previous surgery on the heel
( ^ ) Ç jj 9. Malignant disease
(^ )

10. Diabetes mellitus, severe cardiac or respiratory disease

(^ )

11. Significant abnormalities in hepatic function

Ç'J) Ç j) 12. Participation in another clinical study at the same time.
14. Please indicate the status of this patient
O l 3 . 1 This patient is eligible and gives consent for participation
O l 3 . 2 This patient was missed. Reason: 1
O l 3 .3 This patient is eligible but will not consent (Go to Demographics Form) Reason
(please confirm with patient): 1
'-—-'13.4 This patient is not eligible for participation (Go to Demographics Form)
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ACP® Plantar Fasciitis
Demographics
I Icheck this box if the patient does not consent to having their demographic
information recorded

1. Date of birth:
YYYYMMDD
2. Affected Side: CDright O l e f t O 'b o th
3. Dominant Side: C3right (3 le ft
4. Gender: O m a le *Ofemale
5.1. Height:
5.2 Weight:

*Ocm Clinches
*Okgs *Olbs

6. Have you ever smoked cigarettes? C V e s O no

7. Occupation: Specify:
Classify. (^R equires sustained standing, walking and/or weight
bearing
C^Desk job
C 3other (specify): I
8. Type of employment:
C-W ll-tim e

*Opart-time O stay-at-hom e parent

O R etired

O s tu d e n t

O o th e r : I

CAjnemployed/Social Assistance Ofyolunteer
9. Have you had to reduce your hours of work because of your plantar fasciitis?
O

y es

C^No O

n /A
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10. Haveyou had to modify your duties at work because of your plantar fasciitis?
O y es O n o O n /A

11. Check this box if you are off work for reasons unrelated to your plantar fasciitis EH
If you checked the box, please describe the reason: I
Are you receiving third party compensation? CEVes O

no

12. Date of onset:
YYYYMMDD
13. Activity at onset:
CEActivity o f daily living

Q w ork

C E no specific injury recalled

CEsport Please specify:

14. What previous treatment have you had on your plantar fasciitis?
Please check all that apply.
I Physical Therapy (heat, iontophoresis,
ultrasound, etc.)
1__ lorthoses

CEover-the-counter CEcustom

1 ¡Taping or heel pads
I__ Ishoe modification
l__ E ight splints
EZEopical analgesic or anti-inflammatory gels
1

[prescription analgesics or NSAIDs

1

Local anesthetic injections

1 lElectrocorporeal Shockwave Therapy
EHsurgery
1__ Icorticosteroids

L lo th e r

Please specify:
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ACP® Plantar Fasciitis
Medication Form
Are you taking any medications related to your planter fasciitis? For each medication
listed below, if you are taking the medication then please indicate this by clicking on the
box beside the medication. For each medication that you indicate that you are taking,
please indicate how often you are taking that medication (daily, weekly, occasionally).
Yes No
(^ ) (T j) Non Steroidal Anti-Inflammatory Drugs (NSAIDS)
1 lAspirin

C 3 o a ily C 3 w eek ly C hoccasionally

I

C C oaily O X veek ly O o c c a sio n a lly

Icelebrex

1 llndomethacin (Indocid)

C^Daily C X v eek ly O o c c a sio n a lly

1__ llbuprofen (Advil)

C 3 o a ily O w e e k ly Ch'Occasionali y

I

C 3 ü a ily C H veek ly 'O occasion ally

Ipiclofenac (Voltarin, Arthrotec)

l__ klobicox (Meloxicam)

O O a ily C C w eekly C hoccasionally

I Waproxen (Naprosyn)

O O a ily C H veek ly O o c c a sio n a lly

I

lother (please list): I

C ^D aily O w e e k ly O o c c a sio n a lly

IZHother (please list): I

C^Daily O w e e k ly O o c c a sio n a lly

Are you taking this/these medications because o f your planter fasciitis? O

y

es O

no

Yes No
(^ ) (T jj Pain Killers
1 ffylenol Regular Strength

(O ü a ily O X v eek ly C hoccasionally

1 (Tylenol Extra Strength

G h oaily C h w eek ly 'O occasion ally

I__ lother (please list): I

Ch'Daily C C w eekly O c c a s io n a lly

CHother (please list): I

O 'D a ily 0 \V e e k ly O 'O ccasionally

Are you taking this/these medications because o f your planter fasciitis? O y es C O io
Yes No

Çj) (^ N a r co tics
I

Llorphine

O^Daily O K veekly O )occasionally

C d o x y codone (Percocet, Oxycocet, Endocet) O O a ily C X v eek ly O O ccasion ally
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L i)e m e r o l

O t i a i l y C 3 w eek ly C 3occasionally

EZbodeine

C ^Daily O w e e k ly C 3occasionally

1 halwin

C ^Daily O w e e k ly (^O ccasionally

I

G lD a ily C 3 w eek ly C 3occasionally

klethadone

1__ [lylenol #2, Tylenol #3

O o a i l y O w e e k ly O o c c a sio n a lly

EHother (please list):

C 3 o a ily Q w e e k ly C 3occasionally

LZZlother (please list):

C ^Daily C 3 w eek ly C 3occasionally

Are you taking this/these medications because o f your planter fasciitis?

OYes O

no
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ACP® Plantar Fasciitis
AOFAS Ankle Midfoot Scale
PAIN
O

nc
«lone

O M ild , Occasional
(^M oderate, Daily
G s e v e r e , almost always present

Activity limitations, support requirement
O n o limitations, no support necessary
O n o limitations o f daily activities, limitations in recreational activities, no support
C G im ited daily and recreational activities, cane
C 3severe limitation o f daily and recreational activities, walker, crutches, wheelchairs,
brace

Maximum Walking Distance (blocks)
C^Greater than 6 blocks
O 4-6 blocks
O l - 3 Blocks
C O s s than 1 block

Footwear Requirements
G W sh ion ab le, conventional shoes, no insert required
C^Comfort footwear, shoe insert
C O fo d ified shoes or brace

Walking surfaces
O no difficulty on any surface
C ^Som e difficulty on uneven terrain, stairs, inclines, ladders
C G e v er e difficulty on any terrain, stairs, inclines, ladders
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Gait Abnormality
C ^N one, Slight
C 3ob viou s

CDviarked
Alignment
O G o o d , plantigrade foot, midfoot well aligned
C t a i r , plantigrade foot, some degree o f midfoot malalignment observed, no symptoms
C 3poor, nonplantigrade foot, severe malalignment, symptoms

Foot Alignment
C W eutral
Q pianus
C 3ca v u s
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ACP® Plantar Fasciitis
Plantar Fasciitis Pain/Disability Scale
1. Rate your pain on a scale of 1 to 100.
1

_____________________________________________

2. How many days a week does pain affect your mobility?
3. Is the pain on the surface or deep? C3surface C^Deep
4. Where is your pain located?
O

t oes C W l l o f foot C^M id sole O B o tto m o f heel

5. In the past 6 weeks how often have you had pain?
C^Every other week
O o n c e a week
C 3()nce a day
C 3viany times a day

6. How often since the onset of pain, have you been pain free?
C 3 w eek s
C^Days
O h ours
O M in u te s

7. How long does the pain last?
C 3 only when I overexert
C3pain lasts for less than one hour
C3pain lasts for one to two hours
C^Pain lasts for more than two hours

100
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8. In the past 6 weeks what time o f day is your pain the worst? (Note this specifically for
diagnosis o f different problems)
C 3A lw ays the same
C^O nly in the afternoon
C W t h day and night
C^O nly when you first get up
9. In the past 6 weeks does the pain make it hard to get to sleep?
O n ever 0 ) s o m e nights O W lost nights C W e r y night
10. In the past 6 weeks, how often does your pain awaken you?
O n ever C 3 so m e nights C^M ost nights O fe v e r y night
11. How difficult is it to cope with your pain?
C^Easy to deal with
(O lnconvenient
'O'Troublesome
C )A lm ost Impossible
12. How much does the pain interfere with your athletics or with weight-bearing
activities such as walking?
O n ever C 3occasionally O^Frequently C3Always
13. When you awake, how many minutes must elapse before you can walk comfortably?
O n o time
C ^Less than 10 minutes

O i 1 to 30 minutes
O l t takes over 30 minutes until you are able to walk comfortably
14. Is it more comfortable to walk on your toes than walk flat footed? C ^N o O V e s
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15. Please check the columns below that describes how much your pain affects you in
different conditions.
Activity
Not at all Very little Moderate Severe
Walking in the morning
O
O
Standing up on toes
Driving
Climbing Stairs
Descending Stairs
Reaching up
Bending over
Walking bare foot
Standing after watching a movie
Riding a bike
Running a short distance

O
O
O
O
O
O
O
O
O
O

O
O
O
O
O
O
O
O
O
O

16.How often do you take medication for your pain?
O t e s s than once a week
O s e v e r a l times per week
O o n c e Daily

C W o re than once every day, since injury
17.Describe the medications' affect on your pain.
O l t always stops the pain
O ü e c r e a s e s the pain
C A jsu ally takes the pain away
O ld t t le or no affect on the pain

18. How does the pain affect you emotionally?
C 3 no affect
O l t causes anxiety
O r h e pain worries me daily

O
O
O
O
O
O
O
O
O
O
O

O
O
O
O
O
O
O
O
O
O
O
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G t makes me consider giving up my recreational activities
19. Rate the limitations that your pain/injury affects your daily life style.
O t) o e s not limit your lifestyle
C 3som e activities avoided (ie. riding in car or sitting in stadium for hours)
O

you

avoid all activity due to injury
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ACP® Plantar Fasciitis
Physiotherapy Form
Have you attended physiotherapy since

yourlastvisit?Oy^Ono

Number of Visits
(^ ) > 3 visits per week
1 - 2 visits per
week
C ) < ^ v^s*t Per wee^'

State the estimated number of visits:
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ACP® Plantar Fasciitis
Adverse Event Report
Please use one form for each event.
1.

Date of Onset

YYYY M M D D
2. Please indicate the Adverse Event you are reporting:

Please specify: O su p e rfic ia l

C 3 a . Infection

O oeep

O b . Pain

O c . Swelling
O d . Stiffness
C 3 e . Ligament rupture

O f . Hematoma
O g . Bruising
O h . Numbness at the injection site
O i . Other

Please specify: I

3. Was the patient admitted to the hospital?
Date of
Admission
Date of
Discharge

YYYY

MM

O

no O yes

DD
O r h i s patient has not been discharged from

YYYY M M D D

the hospital

4. List of actions implemented (if more than one action implemented, please indicate
top 3)

Q

.1 Expected to resolve with no treatment

n .2

Patient does not wish to proceed with treatment
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CZk.3 No treatment exists
ED4 .4 Non-surgical treatment
CZI4.5 Medication

Please specify:

□

Please specify: i

4 .6

Surgery

LJ4 .7 Other
i

Please specify:

f"

Select the number of medications associated with this adverse event
Administration

Medication
Name

1

Dose

Unit

1

Duration
Frequency
(no. of
(per day)
days)

1

1

Medication
Name

Route
(oral/IV/etc.)

Dose

1

Administration
Duration
Frequency
Route
(no. of
(per day)
(oral/IV/etc.)
days)

Unit
r~

|

5. Has this adverse event resolved?
O y e s , record the date resolved

YYYY M M D D

C W , ongoing, but expected to resolve (Follow-up required until resolved or study
end)
O no , ongoing, NOT expected to resolve (Follow-up required until resolved or study
end)

